<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Tranexamic acid for percutaneous nephrolithotomy - Cleveland, B - 2023 | Cochrane Library</title> <meta content="Tranexamic acid for percutaneous nephrolithotomy - Cleveland, B - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015122.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Tranexamic acid for percutaneous nephrolithotomy - Cleveland, B - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015122.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015122.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Tranexamic acid for percutaneous nephrolithotomy" name="citation_title"/> <meta content="Brent Cleveland" name="citation_author"/> <meta content="cleve169@umn.edu" name="citation_author_email"/> <meta content="Brett Norling" name="citation_author"/> <meta content="University of Minnesota Medical School" name="citation_author_institution"/> <meta content="Hill Wang" name="citation_author"/> <meta content="University of Minnesota Medical School" name="citation_author_institution"/> <meta content="Vardhil Gandhi" name="citation_author"/> <meta content="University of Alberta" name="citation_author_institution"/> <meta content="Carrie L Price" name="citation_author"/> <meta content="Towson University" name="citation_author_institution"/> <meta content="Michael S Borofsky" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Vernon Pais" name="citation_author"/> <meta content="Dartmouth-Hitchcock Medical Center" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD015122.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/10/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015122.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015122.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015122.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antifibrinolytic Agents [adverse effects]; *Hemostatics; *Kidney Calculi [surgery]; *Nephrolithotomy, Percutaneous; *Tranexamic Acid [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015122.pub2&amp;doi=10.1002/14651858.CD015122.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="JmNqPX1V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015122\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015122\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","th","ms","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015122.pub2",title:"Tranexamic acid for percutaneous nephrolithotomy",firstPublishedDate:"Oct 26, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015122.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015122.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015122.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015122.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015122.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015122.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015122.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015122.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015122.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015122.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1432 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015122.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-sec-0132"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-sec-0126"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/appendices#CD015122-sec-0137"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/supinfo/CD015122-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/supinfo/CD015122-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Tranexamic acid for percutaneous nephrolithotomy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#CD015122-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Brent Cleveland</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#CD015122-cr-0005">Brett Norling</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#CD015122-cr-0006">Hill Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#CD015122-cr-0007">Vardhil Gandhi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#CD015122-cr-0008">Carrie L Price</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#CD015122-cr-0009">Michael S Borofsky</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#CD015122-cr-0010">Vernon Pais</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information#CD015122-cr-0011">Philipp Dahm</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information/en#CD015122-sec-0147">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 October 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015122.pub2">https://doi.org/10.1002/14651858.CD015122.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015122-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015122-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015122-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015122-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015122-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD015122-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015122-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015122-abs-0001" lang="en"> <section id="CD015122-sec-0001"> <h3 class="title" id="CD015122-sec-0001">Background</h3> <p>Percutaneous nephrolithotomy (PCNL) is the gold standard for the treatment of large kidney stones but comes with an increased risk of bleeding compared to other treatments, such as ureteroscopy and shock wave lithotripsy. Tranexamic acid (TXA) is an antifibrinolytic agent that has been used to reduce bleeding complications in other settings. </p> </section> <section id="CD015122-sec-0002"> <h3 class="title" id="CD015122-sec-0002">Objectives</h3> <p>To assess the effects of TXA in individuals with kidney stones undergoing PCNL.</p> </section> <section id="CD015122-sec-0003"> <h3 class="title" id="CD015122-sec-0003">Search methods</h3> <p>We performed a comprehensive literature search of the Cochrane Library, PubMed (including MEDLINE), Embase, Scopus, Global Index Medicus, trials registries, other sources of the grey literature, and conference proceedings. We applied no restrictions on the language of publication nor publication status. The latest search date was 11 May 2023. </p> </section> <section id="CD015122-sec-0004"> <h3 class="title" id="CD015122-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) that compared treatment with PCNL with administration of TXA to placebo (or no TXA) for patients ≥ 18 years old. </p> </section> <section id="CD015122-sec-0005"> <h3 class="title" id="CD015122-sec-0005">Data collection and analysis</h3> <p>Two review authors independently classified studies and abstracted data. Primary outcomes were: blood transfusion, stone‐free rate (SFR), and thromboembolic events (TEEs). Secondary outcomes were: adverse events (AEs), secondary interventions, major surgical complications, minor surgical complications, unplanned hospitalizations or readmissions, and hospital length of stay (LOS). We performed statistical analyzes using a random‐effects model. We rated the certainty of evidence (CoE) according to the GRADE approach using a minimally contextualized approach with predefined thresholds for minimally clinically important differences (MCIDs). </p> </section> <section id="CD015122-sec-0006"> <h3 class="title" id="CD015122-sec-0006">Main results</h3> <p>We analyzed 10 RCTs assessing the effect of systemic TXA in PCNL versus placebo (or no TXA) with 1883 randomized participants. Eight studies were published as full text. One was published in abstract proceedings, but it was separated into two separate studies for the purpose of our analyzes. Average stone surface area ranged 3.45 to 6.62 cm<sup>2</sup>. We also found a single RCT published in full text assessing the effects of topical TXA in PCNL versus placebo (or no TXA) with 400 randomized participants, the results of which are further described in the review. Here we focus only on the results of TXA used systemically. </p> <p><b>Blood transfusion ‐</b> Based on a representative baseline risk of 5.7% for blood transfusions taken from a large presentative observational studies, systemic TXA may reduce blood transfusions (risk ratio (RR) 0.45, 95% confidence interval (CI) 0.27 to 0.76; I<sup>2</sup> = 28%; 9 studies, 1353 participants; low CoE). We assumed an MCID of ≥ 2%. Based on 57 participants per 1000 with placebo (or no TXA) being transfused, this corresponds to 31 fewer (from 42 fewer to 14 fewer) participants being transfused per 1000. </p> <p><b>Stone‐free rate ‐</b> Based on a representative baseline risk of 75.7% for SFR, systemic TXA may increase SFRs (RR 1.11, 95% CI 0.98 to 1.27; I<sup>2</sup> = 62%; 4 studies, 603 participants; low CoE). We assumed an MCID of ≥ 5%. Based on 757 participants per 1000 being stone free with placebo (or no TXA), this corresponds to 83 more (from 15 fewer to 204 more) stone‐free participants per 1000. </p> <p><b>Thromboembolic events ‐</b> There is probably no difference in TEEs (risk difference (RD) 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%; 6 studies, 841 participants; moderate CoE). We assumed an MCID of ≥ 2%. Since there were no thromboembolic events in intervention and/or control groups in 5 out of6 studies, we opted to assess a risk difference with systemic TXA for this outcome. </p> <p><b>Adverse events ‐</b> Systemic TXA may increase AEs (RR 5.22, 95% CI 0.52 to 52.72; I<sup>2</sup> = 75%; 4 studies, 602 participants; low CoE). We assumed an MCID of ≥ 5%. Based on 23 participants per 1000 with placebo (or no TXA) having an adverse event, this corresponds to 98 more (from 11 fewer to 1000 more) participants with adverse events per 1000. </p> <p><b>Secondary interventions ‐</b> Systemic TXA may have little to no effect on secondary interventions (RR 1.15, 95% CI 0.84 to 1.57; I<sup>2</sup> = 0%; 2 studies, 319 participants; low CoE). We assumed an MCID of ≥ 5%. Based on 278 participants per 1000 with placebo (or no TXA) having a secondary intervention, this corresponds to 42 more (from 44 fewer to 158 more) participants with secondary interventions per 1000. </p> <p><b>Major surgical complications ‐</b> Based on a representative baseline risk for major surgical complications of 4.1%, systemic TXA may reduce major surgical complications (RR 0.36, 95% CI 0.21 to 0.62; I<sup>2</sup> = 0%; 5 studies, 733 participants; moderate CoE). We assumed an MCID of ≥ 2%. Based on 41 participants per 1000 with placebo (or no TXA) having a major surgical complication, this corresponds to 26 fewer (from 32 fewer to 16 fewer) participants with major surgical complications per 1000. </p> <p><b>Minor surgical complications ‐</b> Systemic TXA may reduce minor surgical complications (RR 0.71, 95% CI 0.45 to 1.10; I<sup>2</sup> = 76%; 5 studies, 733 participants; low CoE). We assumed an MCID of ≥ 5%. Based on 396 participants per 1000 with placebo (or no TXA) having a minor surgical complication, this corresponds to 115 fewer (from 218 fewer to 40 more) participants with minor surgical complications per 1000. </p> <p><b>Unplanned hospitalizations or readmissions ‐</b> We are very uncertain how unplanned hospitalizations or readmissions are affected (RR 1.55, 95% CI 0.45 to 5.31; I<sup>2</sup> = not applicable; 1 study, 189 participants; very low CoE). We assumed an MCID of ≥ 2%. </p> <p><b>Hospital length of stay ‐</b> Systemic TXA may reduce hospital LOS (mean difference 0.52 days lower, 95% CI 0.93 lower to 0.11 lower; I<sup>2</sup> = 98%; 7 studies, 1151 participants; low CoE). We assumed an MCID of ≥ 0.5 days. </p> </section> <section id="CD015122-sec-0007"> <h3 class="title" id="CD015122-sec-0007">Authors' conclusions</h3> <p>Based on 10 RCTs with substantial methodological limitations that lowered all CoE of effect, we found that systemic TXA in PCNL may reduce blood transfusions, major and minor surgical complications, and hospital LOS, as well as improve SFRs; however, it may increase AEs. We are uncertain about the effects of systemic TXA on other outcomes. Findings of this review should assist urologists and their patients in making informed decisions about the use of TXA in the setting of PCNL. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015122-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015122-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015122-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015122-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015122-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015122-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD015122-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015122-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD015122-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD015122-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015122-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015122-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015122-abs-0002" lang="en"> <h3>What are the benefits and risks of tranexamic acid for percutaneous nephrolithotomy for the treatment of kidney stones? </h3> <p><b>Key messages</b> </p> <p>• Tranexamic acid, when compared to placebo (or no medication), may reduce blood transfusions, surgical complications, and a patient's hospital stay following percutaneous nephrolithotomy. </p> <p>• Tranexamic acid, when compared to placebo (or no medication), may improve the removal of stone material following percutaneous nephrolithotomy but may increase unwanted medication effects. </p> <p>• We do not know if tranexamic acid affects the risk of blood clots forming in other parts of the body following percutaneous nephrolithotomy </p> <p><b>What is percutaneous nephrolithotomy?</b> </p> <p>Percutaneous nephrolithotomy is a treatment method for larger kidney stones. It involves cutting the skin, dilating a path to the stone, and using specialized instruments (like a laser) to break up the stone. Irrigation fluid is used to clear away any blood and help the urologist see better. Though this method is good at removing stones, it can also cause complications, including bleeding, which may require a blood transfusion. </p> <p><b>What is tranexamic acid?</b> </p> <p>Tranexamic acid is a medication that can reduce the amount of bleeding and, therefore, the risk of a transfusion. It has been used in the treatment of bleeding disorders and to decrease bleeding in heart and bone/joint surgeries. It may be beneficial to use tranexamic acid during percutaneous nephrolithotomy. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out if giving tranexamic acid was better (or worse) than not giving tranexamic acid. The main outcomes we were interested in were blood transfusions, completeness of stone removal, and the risk of blood clots forming in other parts of the body. We also studied unwanted medication effects, the need for more stone procedures, major and minor surgical complications, unplanned returns to the hospital, and length of stay in the hospital. </p> <p><b>What did we do?</b> </p> <p>We searched for all studies in which participants had a percutaneous nephrolithotomy for large stones, and chance determined whether they were given tranexamic acid or no tranexamic acid. We compared and summarized the results of the studies and rated our confidence in the evidence based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 10 studies that used tranexamic acid as an infusion by vein and one study that added tranexamic acid to the irrigation fluid. Based on these studies, tranexamic acid may reduce blood transfusions and improve stone removal. However, we do not know if tranexamic acid affects blood clots forming in other parts of the body when infused by a vein, or added to the irrigation fluid used for percutaneous nephrolithotomy. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We have little confidence in most of the evidence, and for some of the results, we are confident in the evidence. Reasons for low confidence include concerns about whether participants in both groups were managed and evaluated the same way. Also, in some instances, the results of the included studies were quite different, the studies were small, or there were not enough studies to be sure of the effect. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up‐to‐date to 11 May 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015122-sec-0132" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015122-sec-0132"></div> <h3 class="title" id="CD015122-sec-0133">Implications for practice</h3> <section id="CD015122-sec-0133"> <p>Findings of this review would suggest that both systemic and topical use of tranexamic acid (TXA) may reduce the risk of transfusion and improve stone‐free rates when performing percutaneous nephrolithotomy (PCNL). Not surprisingly, a larger absolute benefit is seen in individuals at higher risk for bleeding. These may be patients requiring more than a single access tract, a complex anatomy, or a large stone burden. Additional benefits of TXA use may be in the reduced rates of major and minor surgical complications. </p> <p>The most important concern when using TXA may stem from the uncertainty as to whether, and to what extent, the risk of venous thromboembolism may be increased with systemic use, even if the risk in absolute terms may be low. We also found an increased risk of adverse events (overall) when comparing systemic TXA with usual care. These potential harms should inform the trade‐off of desirable and undesirable effects when it comes to clinical decision‐making. </p> </section> <h3 class="title" id="CD015122-sec-0134">Implications for research</h3> <section id="CD015122-sec-0134"> <p>The mostly low‐quality of evidence for most outcomes reflects both the limited methodological quality of existing trials as well as imprecision due to overall small sample sizes and low event rates. Therefore, additional high‐quality trials are needed in this space. Future studies should have registered protocols, apply concealed allocation at the time of study enrollment, and blind all relevant parties including participants, study personnel, and outcome assessors. The studies should also be sufficiently powered not only for the overall analyzes, but for secondary, and predefined subgroup analysis based on variables such as stone size, stone location, and access size. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015122-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015122-sec-0008"></div> <div class="table" id="CD015122-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Systemic TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Systemic TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> percutaneous nephrolithotomy <br/><b>Setting:</b> inpatient <br/><b>Intervention:</b> Systemic TXA <br/><b>Comparison:</b> No TXA (placebo or usual care) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interpretation</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with No TXA (placebo or usual care)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with Systemic TXA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Blood transfusion</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>1353<br/>(9 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b><br/>(0.27 to 0.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA probably reduces transfusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>61 fewer per 1000</b><br/>(81 fewer to 27 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce transfusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 fewer per 1000</b><br/>(42 fewer to 14 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Stone‐free rate</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>603<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.11</b><br/>(0.98 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may increase stone‐free rates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>620 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>68 more per 1000</b><br/>(12 fewer to 168 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may increase stone‐free rates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>83 more per 1000</b><br/>(15 fewer to 204 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Thromboembolic events</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>841<br/>(6 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RD0.00</b><br/>(‐0.01 to 0.01)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is probably no difference in how TXA effects thromboembolic events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to estimate</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>602<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.22</b><br/>(0.52 to 52.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may increase adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>98 more per 1000</b><br/>(11 fewer to 1,000 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Secondary interventions</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>319<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b><br/>(0.84 to 1.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may have little to no effect on secondary interventions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42 more per 1000</b><br/>(44 fewer to 158 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Major surgical complications</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>733<br/>(5 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.36</b><br/>(0.21 to 0.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA probably reduces major surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>83 fewer per 1000</b><br/>(103 fewer to 49 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce major surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 fewer per 1000</b><br/>(32 fewer to 16 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor surgical complications</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>733<br/>(5 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.71</b><br/>(0.45 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce minor surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>115 fewer per 1000</b><br/>(218 fewer to 40 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Unplanned hospitalizations or readmissions</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>189<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Verylow</b><sup>a,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.55</b><br/>(0.45 to 5.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are very uncertain how TXA effects unplanned hospitalizations or readmissions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 more per 1000</b><br/>(23 fewer to 180 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital length of stay</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 0.5 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1151<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean hospital length of stay was 4.72 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.52 days lower</b><br/>(0.93 lower to 0.11 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA may reduce hospital length of stay</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MCID:</b> minimally clinically important difference; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>RD:</b> risk difference; <b>TXA:</b> tranexamic acid </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rated down by one level (‐1) for risk of bias due to concerns over performance, detection and/or selective reporting bias. </p> <p><sup>b</sup>Based on pooled control event rate in the non‐TXA group. </p> <p><sup>c</sup>Rated down by one level (‐1) for imprecision due to wide confidence intervals consistent with both a decrease and no change. </p> <p><sup>d</sup>Based on large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>). </p> <p><sup>e</sup>Rated down by one level (‐1) for inconsistency due to clinically relevant inconsistency and high I‐square; we did not rate down further for imprecision. </p> <p><sup>f</sup>Risk difference was calculated for thromboembolic events as there were no thromboembolic events in intervention and/or control groups in 5 out of 6 studies. </p> <p><sup>g</sup>Rated down by one level (‐1) for imprecision due to wide confidence intervals consistent with both an increase and no change. </p> <p><sup>h</sup>Rated down by two levels (‐2) for imprecision due to wide confidence intervals consistent with an increase, no change or a decrease. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015122-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topical TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Percutaneous nephrolithotomy <br/><b>Setting:</b> Inpatients<br/><b>Intervention:</b> Topical TXA <br/><b>Comparison:</b> No TXA (placebo or usual care) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interpretation</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with No TXA (placebo or usual care)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with Topical TXA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Blood transfusion</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.40</b><br/>(0.20 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA probably reduces blood transfusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 fewer per 1000</b><br/>(100 fewer to 24 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce blood transfusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 fewer per 1000</b><br/>(46 fewer to 11 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Stone‐free rate</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b><br/>(0.99 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may improve stone‐free rates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>57 more per 1000</b><br/>(8 fewer to 139 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may improve stone‐free rates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53 more per 1000</b><br/>(8 fewer to 129 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Thromboembolic events</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RD 0.00</b> (‐0.01 to 0.01)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is probably no difference in how TXA effects thromboembolic events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to estimate</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RD 0.00</b> (‐0.01 to 0.01)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is probably no difference in how TXA effects adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to estimate</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Secondary interventions</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We found no evidence for the outcome of secondary interventions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Major surgical complications</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.69</b><br/>(0.45 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce major surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>65 fewer per 1000</b><br/>(116 fewer to 13 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce major surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 fewer per 1000</b><br/>(23 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor surgical complications</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.73</b><br/>(0.59 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce minor surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>140 fewer per 1000</b><br/>(213 fewer to 47 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Unplanned hospitalizations or readmissions</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We found no evidence for the outcome of unplanned hospitalizations or readmissions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital length of stay</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 0.5 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean hospital length of stay was 3.39 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.26 days lower</b><br/>(1.49 lower to 1.03 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA probably reduces hospital length of stay</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MCID:</b> minimally clinically important difference; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>RD:</b> risk difference; <b>TXA:</b> tranexamic acid </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rated down by one level (‐1) for to risk of bias due to concerns over performance, detection and/or selective reporting bias. </p> <p><sup>b</sup>Based on pooled control event rate in the non‐TXA group. </p> <p><sup>c</sup>Rated down by one level (‐1) for imprecision due to wide confidence intervals consistent with both a decrease and no change. </p> <p><sup>d</sup>Based on large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>). </p> <p><sup>e</sup>Rated down by one level (‐1) for imprecision due to wide confidence intervals consistent with both an increase and no change. </p> <p><sup>f</sup>Risk difference was calculated for thromboembolic events as there were no thromboembolic events in the intervention nor the control groups. </p> <p><sup>g</sup> Risk difference was calculated for adverse events as there were no adverse events in the intervention nor the control groups. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015122-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015122-sec-0009"></div> <section id="CD015122-sec-0010"> <h3 class="title" id="CD015122-sec-0010">Description of the condition</h3> <section id="CD015122-sec-0011"> <h4 class="title">Nephrolithiasis and percutaneous nephrolithotomy</h4> <p>Nephrolithiasis is the deposition of hard crystals in the urinary collecting system, often beginning with supersaturated urine due to dehydration, dietary habits, and metabolic disorders (<a href="./references#CD015122-bbs2-0034" title="DawsonCH , TomsonCR . Kidney stone disease: pathophysiology, investigation and medical treatment. Clinical Medicine (London, England)2012;12(5):467-71.">Dawson 2012</a>). In the USA, lifetime prevalence has been reported at 8.8%, with 10.6% of men and 7.1% of women experiencing a kidney stone over their lifetime and up to 50% of individuals having stone recurrence within 10 years (<a href="./references#CD015122-bbs2-0086" title="PearleMS , GoldfarbDS , AssimosDG , CurhanG , Denu-CioccaCJ , MatlagaBR , et al. Medical management of kidney stones: AUA Guideline. Journal of Urology2014;192(2):316-24.">Pearle 2014</a>; <a href="./references#CD015122-bbs2-0096" title="ScalesCD , SmithAC , HanleyJM , SaigalCS . Prevalence of kidney stones in the United States. European Urology2012;62(1):160-5. [PMID: 22498635]">Scales 2012</a>). Kidney stone prevalence disparately affects American men more than women, but prevalence in females is increasing (<a href="./references#CD015122-bbs2-0104" title="StropeSA , Wolf JS Jr, HollenbeckBK . Changes in gender distribution of urinary stone disease. Urology2010;75(3):543-6, 546 e1. [PMID: 19854493]">Strope 2010</a>). Nephrolithiasis in the USA also varies based on race and ethnicity, with rates of 10.3%, 4.3%, and 6.4% for White, non‐Hispanic Black, and Hispanic individuals, respectively (<a href="./references#CD015122-bbs2-0096" title="ScalesCD , SmithAC , HanleyJM , SaigalCS . Prevalence of kidney stones in the United States. European Urology2012;62(1):160-5. [PMID: 22498635]">Scales 2012</a>). Lastly, the annual economic burden of nephrolithiasis in the USA has been estimated to exceed 5 billion US dollars (<a href="./references#CD015122-bbs2-0057" title="HyamsES , MatlagaBR . Economic impact of urinary stones. Translational Andrology and Urology2014;3(3):278-83.">Hyams 2014</a>). </p> <p>Treatment strategies for nephrolithiasis include medical expulsive therapy and surgical intervention. Options for surgical intervention include extracorporeal shock wave lithotripsy (ESWL), ureteroscopy, and percutaneous nephrolithotomy (PCNL). PCNL refers to the fragmentation and removal of kidney stones via access through a skin incision, dilation of a tract, and use of endoscopic instruments. In contrast to other surgical techniques, PCNL is regarded as the gold standard for treatment of large renal stones (<a href="./references#CD015122-bbs2-0045" title="GhaniKR , AndonianS , BultitudeM , DesaiM , GiustiG , OkhunovZ , et al. Percutaneous nephrolithotomy: update, trends, and future directions. European Urology2016;70(2):382-96. [PMID: 26876328]">Ghani 2016</a>). </p> <p>Imaging of the affected kidney, most commonly with an abdominal computerized tomography (CT) scan, and urinalysis with possible urine culture are usually obtained prior to PCNL (<a href="./references#CD015122-bbs2-0066" title="KoR , SoucyF , DenstedtJD , RazviH . Percutaneous nephrolithotomy made easier: a practical guide, tips and tricks. British Journal of Urology International2008;101(5):535-9.">Ko 2008</a>; <a href="./references#CD015122-bbs2-0075" title="MarcovichR , SmithAD . Percutaneous renal access: tips and tricks. British Journal of Urology International2005;95 (Suppl 2):78-84.">Marcovich 2005</a>; <a href="./references#CD015122-bbs2-0085" title="ParkS , PearleMS . Imaging for percutaneous renal access and management of renal calculi. Urologic Clinics of North America2006;33(3):353-64.">Park 2006</a>). Subsequent treatment of any urinary tract infection and discontinuation of anticoagulation are indicated preoperatively. PCNL is most commonly performed under general anesthesia with broad‐spectrum antibiotics to decrease the risk for infection (<a href="./references#CD015122-bbs2-0066" title="KoR , SoucyF , DenstedtJD , RazviH . Percutaneous nephrolithotomy made easier: a practical guide, tips and tricks. British Journal of Urology International2008;101(5):535-9.">Ko 2008</a>; <a href="./references#CD015122-bbs2-0076" title="MariappanP , SmithG , MoussaSA , TolleyDA . One week of ciprofloxacin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. British Journal of Urology International2006;98(5):1075-9.">Mariappan 2006</a>). Percutaneous access, usually from the posterior flank, may be obtained utilizing fluoroscopic, ultrasound or endoscopic guidance, or a combination of these techniques. Through the percutaneous access, a tract is dilated, and a sheath is placed, typically varying from 18 French (Fr) to 30 Fr (1 Fr is also known as 1 Charrière (Ch) and is equivalent to one third of a millimeter (mm). Nephroscopy through the sheath is performed to remove or fragment renal stones. Methods of fragmentation include laser, ultrasonic or electrohydraulic lithotripsy (<a href="./references#CD015122-bbs2-0044" title="GanpuleAP , VijayakumarM , MalpaniA , DesaiMR . Percutaneous nephrolithotomy (PCNL) a critical review. International Journal of Surgery2016;36:660-4. [PMID: 27856356]">Ganpule 2016</a>). Irrigation and stone graspers may be used to remove smaller stones or stone fragments. </p> <p>Although a tubeless PCNL is possible, which refers to the omission of a postoperative nephrostomy tube (a catheter inserted through the skin into the kidney), most procedures end with the placement of a nephrostomy tube or a ureteral stent (<a href="./references#CD015122-bbs2-0064" title="KimSC , KuoRL , LingemanJE . Percutaneous nephrolithotomy: an update. Current Opinion in Urology2003;13(3):235-41.">Kim 2003</a>; <a href="./references#CD015122-bbs2-0066" title="KoR , SoucyF , DenstedtJD , RazviH . Percutaneous nephrolithotomy made easier: a practical guide, tips and tricks. British Journal of Urology International2008;101(5):535-9.">Ko 2008</a>). A recent meta‐analysis of 16 randomized controlled trials (RCTs) showed benefits in hemoglobin changes and hospital stay when "tubeless" PCNL (absence of nephrostomy tube upon completion of surgery) was performed (<a href="./references#CD015122-bbs2-0071" title="LeeJY , JehSU , KimMD , KangDH , KwonJK , HamWS , et al. Intraoperative and postoperative feasibility and safety of total tubeless, tubeless, small-bore tube, and standard percutaneous nephrolithotomy: a systematic review and network meta-analysis of 16 randomized controlled trials. BMC Urology2017;17(1):48. [PMID: 28655317]">Lee 2017</a>). However, a recently published Cochrane Review (<a href="./references#CD015122-bbs2-0114" title="WilhelmK , HeinS , KunathF , SchoenthalerM , SchmidtS . Totally tubeless, tubeless, and tubed percutaneous nephrolithotomy for treating kidney stones. Cochrane Database of Systematic Reviews2023, Issue 7. Art. No: CD012607. [DOI: 10.1002/14651858.CD012607.pub2]">Wilhelm 2023</a>) was very uncertain (very low CoE) of the effect of "tubeless" and "totally tubeless" PCNL (absence of nephrostomy tube and ureteral stent) on blood loss, although it did find "tubeless" may reduce and "totally tubeless" likely reduces length of hospital stay (low‐ and moderate‐CoE, respectively). Postoperative imaging, such as a non‐contrast CT or nephrostogram, is often used to assess stone clearance (<a href="./references#CD015122-bbs2-0066" title="KoR , SoucyF , DenstedtJD , RazviH . Percutaneous nephrolithotomy made easier: a practical guide, tips and tricks. British Journal of Urology International2008;101(5):535-9.">Ko 2008</a>). If the person is determined to be stone‐free, the tube or stent can be removed, otherwise they may be used for secondary procedures. </p> <p>Typical indications for PCNL are stones larger than 2 cm, staghorn calculi, and partial staghorn calculi, but this technique may also be recommended for large lower‐pole renal stones (<a href="./references#CD015122-bbs2-0044" title="GanpuleAP , VijayakumarM , MalpaniA , DesaiMR . Percutaneous nephrolithotomy (PCNL) a critical review. International Journal of Surgery2016;36:660-4. [PMID: 27856356]">Ganpule 2016</a>; <a href="./references#CD015122-bbs2-0109" title="TürkC , NeisiusA , PetříkA , SeitzC , SkolarikosA , SomaniB , et al. EAU guidelines on urolithiasis. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4.">Turk 2021</a>). Compared with other modalities, PCNL is the treatment of choice for bulky urinary stones because of its cost‐effectiveness, higher stone‐clearance rate, and lower resulting morbidity (<a href="./references#CD015122-bbs2-0045" title="GhaniKR , AndonianS , BultitudeM , DesaiM , GiustiG , OkhunovZ , et al. Percutaneous nephrolithotomy: update, trends, and future directions. European Urology2016;70(2):382-96. [PMID: 26876328]">Ghani 2016</a>). Depending on individual characteristics and definition of stone clearance, stone‐free rates after PCNL have been estimated to be between 76% and 90% (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>; <a href="./references#CD015122-bbs2-0045" title="GhaniKR , AndonianS , BultitudeM , DesaiM , GiustiG , OkhunovZ , et al. Percutaneous nephrolithotomy: update, trends, and future directions. European Urology2016;70(2):382-96. [PMID: 26876328]">Ghani 2016</a>). </p> <p>Despite excellent stone‐free rates and improvement in outcomes over the years, PCNL is associated with higher complication rates compared to retrograde intrarenal surgery (RIRS), such as ureteroscopy, or ESWL, although increasing miniaturization may change this (<a href="./references#CD015122-bbs2-0101" title="SoderbergL , DingM , ParkerR , BorofskyM , PaisV , DahmP . Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults. Cochrane Database of Systematic Reviews2019, Issue 10. Art. No: CD013445. [DOI: 10.1002/14651858.CD013445]">Soderberg 2019</a>). Complications can be related either to access or stone removal (<a href="./references#CD015122-bbs2-0044" title="GanpuleAP , VijayakumarM , MalpaniA , DesaiMR . Percutaneous nephrolithotomy (PCNL) a critical review. International Journal of Surgery2016;36:660-4. [PMID: 27856356]">Ganpule 2016</a>). According to a systematic review of nearly 12,000 participants, the most common complications of PCNL include: fever (10.8%), blood transfusion (7%), thoracic complication (1.5%), sepsis (0.5%), organ injury (0.4%), embolization (0.4%), urinoma (0.2%), and death (0.05%) (<a href="./references#CD015122-bbs2-0098" title="SeitzC , DesaiM , HackerA , HakenbergOW , LiatsikosE , NageleU , et al. Incidence, prevention, and management of complications following percutaneous nephrolitholapaxy. European Urology2012;61(1):146-58. [PMID: 21978422]">Seitz 2012</a>). </p> <p>The kidneys are highly vascularized, so bleeding is a common complication during PCNL and usually occurs due to puncture or laceration of the parenchymal vessel during tract dilation or from kidney tear as a result of excessive nephrostomy sheath bending (<a href="./references#CD015122-bbs2-0069" title="KyriazisI , PanagopoulosV , KallidonisP , ÖzsoyM , VasilasM , LiatsikosE . Complications in percutaneous nephrolithotomy. World Journal of Urology2015;25(1):1069-77. [PMID: 25218854]">Kyriazis 2014</a>). Bleeding can typically be managed conservatively with diuretics, intravenous hydration, and clamping of the nephrostomy tube (<a href="./references#CD015122-bbs2-0039" title="El TayebMM , KnoedlerJJ , KrambeckAE , PaonessaJE , MellonMJ , LingemanJE . Vascular complications after percutaneous nephrolithotomy: 10 years of experience. Urology2015;85(4):777-81. [PMID: 25704996]">El Tayeb 2015</a>). Severe bleeding and hemorrhagic complications associated with PCNL most commonly occur perioperatively, immediately postoperatively, or a few days following the procedure (<a href="./references#CD015122-bbs2-0069" title="KyriazisI , PanagopoulosV , KallidonisP , ÖzsoyM , VasilasM , LiatsikosE . Complications in percutaneous nephrolithotomy. World Journal of Urology2015;25(1):1069-77. [PMID: 25218854]">Kyriazis 2014</a>). Severe delayed bleeding is rare and usually due to unhealed parenchymal vessel, which can often be managed conservatively. Selective embolization is used when conservative measures fail, or if iatrogenic arteriovenous fistulas or pseudoaneurysms are identified as underlying etiologies (<a href="./references#CD015122-bbs2-0069" title="KyriazisI , PanagopoulosV , KallidonisP , ÖzsoyM , VasilasM , LiatsikosE . Complications in percutaneous nephrolithotomy. World Journal of Urology2015;25(1):1069-77. [PMID: 25218854]">Kyriazis 2014</a>). </p> <p>Rates of blood transfusion following PCNL have been reported to vary between 1% and 11%, with recent studies citing rates less than 2% (<a href="./references#CD015122-bbs2-0106" title="TaylorE , MillerJ , ChiT , StollerML . Complications associated with percutaneous nephrolithotomy. Translational Andrology and Urology2012;1(4):223-8. [PMID: 26816715]">Taylor 2012</a>; <a href="./references#CD015122-bbs2-0039" title="El TayebMM , KnoedlerJJ , KrambeckAE , PaonessaJE , MellonMJ , LingemanJE . Vascular complications after percutaneous nephrolithotomy: 10 years of experience. Urology2015;85(4):777-81. [PMID: 25704996]">El Tayeb 2015</a>). Among studies looking at severe bleeding, blood transfusion, and vascular complications following PCNL, risk factors identified included high body mass index (BMI), low preoperative hemoglobin, stone size, staghorn stone, stone position, degree of preoperative hydronephrosis, solitary kidney, upper caliceal puncture, multiple punctures, larger tract size, renal pelvic perforation, operation time, and inexperienced surgeon (<a href="./references#CD015122-bbs2-0040" title="El-NahasAR , ShokeirAA , El-AssmyAM , MohsenT , ShomaAM , ErakyI , et al. Post-percutaneous nephrolithotomy extensive hemorrhage: a study of risk factors. Journal of Urology2007;177(2):576-9. [PMID: 17222636]">El‐Nahas 2007</a>; <a href="./references#CD015122-bbs2-0070" title="LeeJK , KimBS , ParkYK . Predictive factors for bleeding during percutaneous nephrolithotomy. Korean Journal of Urology2013;54(7):448-53.">Lee 2013</a>; <a href="./references#CD015122-bbs2-0098" title="SeitzC , DesaiM , HackerA , HakenbergOW , LiatsikosE , NageleU , et al. Incidence, prevention, and management of complications following percutaneous nephrolitholapaxy. European Urology2012;61(1):146-58. [PMID: 21978422]">Seitz 2012</a>; <a href="./references#CD015122-bbs2-0102" title="SrivastavaA , SinghKJ , SuriA , DubeyD , KumarA , KapoorR , et al. Vascular complications after percutaneous nephrolithotomy: are there any predictive factors?Urology2005;66(1):38-40.">Srivastava 2005</a>). However, a recent large retrospective cohort study of over 3300 PCNLs found no predictive factors for vascular complications following PCNL (<a href="./references#CD015122-bbs2-0039" title="El TayebMM , KnoedlerJJ , KrambeckAE , PaonessaJE , MellonMJ , LingemanJE . Vascular complications after percutaneous nephrolithotomy: 10 years of experience. Urology2015;85(4):777-81. [PMID: 25704996]">El Tayeb 2015</a>). </p> </section> </section> <section id="CD015122-sec-0012"> <h3 class="title" id="CD015122-sec-0012">Description of the intervention</h3> <p>Tranexamic acid (TXA) is a synthetic lysine‐analogue antifibrinolytic, first patented in 1957 (<a href="./references#CD015122-bbs2-0082" title="NgW , JerathA , WąsowiczM . Tranexamic acid: a clinical review. Anaesthesiology Intensive Therapy2015;47(4):339-50.">Ng 2015</a>). Its mechanism of action is competitive inhibition of plasminogen activation by attaching to a plasminogen lysine binding site, thereby preventing the conversion of plasminogen to plasmin. Normally, plasmin attaches to fibrin leading to fibrinolysis. When the conversion of plasminogen to plasmin is inhibited by TXA, fibrinolysis is reduced, thereby stabilizing coagulation and decreasing hemorrhage (<a href="./references#CD015122-bbs2-0103" title="StansfieldR , MorrisD , JesulolaE . The use of tranexamic acid (TXA) for the management of hemorrhage in trauma patients in the prehospital environment: literature review and descriptive analysis of principal themes. Shock2020;53(3):277-83.">Stansfield 2020</a>). </p> <p>TXA can be administered via enteral, intravenous, and topical routes. It was first introduced clinically to aid in the management of people with bleeding disorders such as hemophilia, to reduce blood loss in oral surgery (<a href="./references#CD015122-bbs2-0103" title="StansfieldR , MorrisD , JesulolaE . The use of tranexamic acid (TXA) for the management of hemorrhage in trauma patients in the prehospital environment: literature review and descriptive analysis of principal themes. Shock2020;53(3):277-83.">Stansfield 2020</a>). It has since been used to prevent traumatic exsanguination, as well as in the treatment of gynecologic bleeding disorders, postpartum hemorrhage, and gastrointestinal bleeding (<a href="./references#CD015122-bbs2-0077" title="McCormackPL . Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs2012;72(5):585-617.">McCormack 2012</a>; <a href="./references#CD015122-bbs2-0080" title="MousaHA , BlumJ , Abou El SenounG , ShakurH , AlfirevicZ . Treatment for primary postpartum haemorrhage. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD003249. [DOI: 10.1002/14651858.CD003249.pub3]">Mousa 2014</a>). In the field of surgery, TXA has been adopted in cardiac, orthopedic, and urologic applications, including open prostatectomy and transurethral resection of prostate (<a href="./references#CD015122-bbs2-0033" title="CrescentiA , BorghiG , BignamiE , BertarelliG , LandoniG , CasiraghiGM , et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. BMJ2011;343:d5701. [DOI: 10.1136/bmj.d5701]">Crescenti 2011</a>; <a href="./references#CD015122-bbs2-0077" title="McCormackPL . Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs2012;72(5):585-617.">McCormack 2012</a>). Prior Cochrane Reviews have examined the use of TXA in a multitude clinical applications with varied findings that were often limited by small numbers of studies (<a href="./references#CD015122-bbs2-0026" title="BaharogluMI , GermansMR , RinkelGJ , AlgraA , VermeulenM , vanGijnJ , et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD001245. [DOI: 10.1002/14651858.CD001245.pub2]">Baharoglu 2013</a>; <a href="./references#CD015122-bbs2-0028" title="BennettC , KlingenbergSL , LangholzE , GluudLL . Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD006640. [DOI: 10.1002/14651858.CD006640.pub3]">Bennett 2014</a>; <a href="./references#CD015122-bbs2-0029" title="Bryant-SmithAC , LethabyA , FarquharC , HickeyM . Antifibrinolytics for heavy menstrual bleeding. Cochrane Database of Systematic Reviews2018, Issue 4. Art. No: CD000249. [DOI: 10.1002/14651858.CD000249.pub2]">Bryant‐Smith 2018</a>; <a href="./references#CD015122-bbs2-0041" title="EstcourtLJ , DesboroughM , BrunskillSJ , DoreeC , HopewellS , MurphyMF , et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. Cochrane Database of Systematic Reviews2016, Issue 3. Art. No: CD009733. [DOI: 10.1002/14651858.CD009733.pub3]">Estcourt 2016</a>; <a href="./references#CD015122-bbs2-0059" title="JosephJ , Martinez-DevesaP , BelloriniJ , BurtonMJ . Tranexamic acid for patients with nasal haemorrhage (epistaxis). Cochrane Database of Systematic Reviews2018, Issue 12. Art. No: CD004328. [DOI: 10.1002/14651858.CD004328.pub3]">Joseph 2018</a>; <a href="./references#CD015122-bbs2-0061" title="KerK , BeecherD , RobertsI . Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD010562. [DOI: 10.1002/14651858.CD010562.pub2]">Ker 2013</a>; <a href="./references#CD015122-bbs2-0062" title="KerK , RobertsI , ShakurH , CoatsTJ . Antifibrinolytic drugs for acute traumatic injury. Cochrane Database of Systematic Reviews2015, Issue 5. Art. No: CD004896. [DOI: 10.1002/14651858.CD004896.pub3]">Ker 2015</a>; <a href="./references#CD015122-bbs2-0063" title="KietpeerakoolC , SupokenA , LaopaiboonM , LumbiganonP . Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. Cochrane Database of Systematic Reviews2016, Issue 1. Art. No: CD011732. [DOI: 10.1002/14651858.CD011732.pub2]">Kietpeerakool 2016</a>; <a href="./references#CD015122-bbs2-0067" title="KongnyuyEJ , WiysongeCS . Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database of Systematic Reviews2014, Issue 8. Art. No: CD005355. [DOI: 10.1002/14651858.CD005355.pub5]">Kongnyuy 2014</a>; <a href="./references#CD015122-bbs2-0078" title="McNicolED , TzortzopoulouA , SchumannR , CarrDB , KalraA . Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD006883. [DOI: 10.1002/14651858.CD006883.pub3]">McNicol 2016</a>; <a href="./references#CD015122-bbs2-0080" title="MousaHA , BlumJ , Abou El SenounG , ShakurH , AlfirevicZ . Treatment for primary postpartum haemorrhage. Cochrane Database of Systematic Reviews2014, Issue 2. Art. No: CD003249. [DOI: 10.1002/14651858.CD003249.pub3]">Mousa 2014</a>; <a href="./references#CD015122-bbs2-0084" title="NovikovaN , Hofmeyr GJ , CluverC . Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews2015, Issue 6. Art. No: CD007872. [DOI: 10.1002/14651858.CD007872.pub3]">Novikova 2015</a>; <a href="./references#CD015122-bbs2-0087" title="PerelP , KerK , Morales UribeCH , RobertsI . Tranexamic acid for reducing mortality in emergency and urgent surgery. Cochrane Database of Systematic Reviews2013, Issue 3. Art. No: CD010245. [DOI: 10.1002/14651858.CD010245.pub2]">Perel 2013</a>; <a href="./references#CD015122-bbs2-0090" title="PrutskyG , DomecqJP , SalazarCA , AccinelliR . Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD008711. [DOI: 10.1002/14651858.CD008711.pub3]">Prutsky 2016</a>; <a href="./references#CD015122-bbs2-0092" title="RayS , RayA . Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders. Cochrane Database of Systematic Reviews2014, Issue 11. Art. No: CD010338. [DOI: 10.1002/14651858.CD010338.pub2]">Ray 2014</a>; <a href="./references#CD015122-bbs2-0094" title="RobertsI , ShakurH , KerK , CoatsT . Antifibrinolytic drugs for acute traumatic injury. Cochrane Database of Systematic Reviews2012, Issue 1. Art. No: CD004896. [DOI: 10.1002/14651858.CD004896.pub3]">Roberts 2012</a>; <a href="./references#CD015122-bbs2-0099" title="ShakurH , BeaumontD , PavordS , Gayet-AgeronA , KerK , MousaHA . Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012964. [DOI: 10.1002/14651858.CD012964]">Shakur 2018</a>; <a href="./references#CD015122-bbs2-0113" title="WardropD , EstcourtLJ , BrunskillSJ , DoreeC , TrivellaM , StanworthS , et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD009733. [DOI: 10.1002/14651858.CD009733.pub3]">Wardrop 2013</a>; <a href="./references#CD015122-bbs2-0110" title="vanGalenKP , EngelenET , Mauser-BunschotenEP , vanEsRJ , SchutgensRE . Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database of Systematic Reviews2015, Issue 12. Art. No: CD011385. [DOI: 10.1002/14651858.CD011385.pub2]">van Galen 2015</a>). </p> <section id="CD015122-sec-0013"> <h4 class="title">Adverse effects of the intervention</h4> <p>The most common side effects of TXA include nausea and diarrhea, both of which can usually be prevented by decreasing the dose (<a href="./references#CD015122-bbs2-0108" title="TengbornL , BlombäckM , BerntorpE . Tranexamic acid – an old drug still going strong and making a revival. Thrombosis Research2015;135(2):231-42.">Tengborn 2015</a>); however, minor perioperative side effects are challenging to evaluate due to the difficulty in isolating TXA as the causative agent. More severe side effects include hypersensitivity reactions, cerebrovascular infarction, myocardial infarction, pulmonary embolism (PE), deep vein thrombosis (DVT), acute renal cortical necrosis, and seizure (<a href="./references#CD015122-bbs2-0030" title="CalapaiG , GangemiS , MannucciC , MinciulloPL , CasciaroM , CalapaiF , et al. Systematic review of tranexamic acid adverse reactions. Journal of Pharmacovigilance2015;3(4):1000171. [DOI: 10.4172/2329-6887.1000171]">Calapai 2015</a>). </p> <p>Due to its antifibrinolytic effect, a major concern with TXA use is the propagation of the coagulation cascade resulting in venous thromboembolic events (VTE). Despite this concern, two systematic reviews on the use of TXA during surgical procedures showed that TXA was not correlated to increased risk for VTE during or after surgery (<a href="./references#CD015122-bbs2-0043" title="FranchiniM , MengoliC , MariettaM , MaranoG , VaglioS , PupellaS , et al. Safety of intravenous tranexamic acid in patients undergoing major orthopaedic surgery: a meta-analysis of randomised controlled trials. Blood Transfusion2018;16(1):36-43. [DOI: 10.2450//2017.0219-17]">Franchini 2018</a>; <a href="./references#CD015122-bbs2-0115" title="YatesJ , PerelmanI , KhairS , TaylorJ , LampronJ , TinmouthA , et al. Exclusion criteria and adverse events in perioperative trials of tranexamic acid: a systematic review and meta‐analysis. Transfusion2019;59(2):806-24.">Yates 2019</a>). Furthermore, a large cohort study of more than 800,000 people undergoing knee and hip arthroplasty found no difference in VTE rates in people treated with or without TXA (<a href="./references#CD015122-bbs2-0088" title="PoeranJ , RasulR , SuzukiS , DanningerT , MazumdarM , OppererM , et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ2014;349:g4829.">Poeran 2014</a>). Specifically within urologic literature, studies examining people undergoing radical cystectomy and radical retropubic prostatectomy found no differences in the rates of VTE among people treated with TXA compared to those who did not receive it (<a href="./references#CD015122-bbs2-0033" title="CrescentiA , BorghiG , BignamiE , BertarelliG , LandoniG , CasiraghiGM , et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. BMJ2011;343:d5701. [DOI: 10.1136/bmj.d5701]">Crescenti 2011</a>; <a href="./references#CD015122-bbs2-0116" title="ZaidHB , YangDY , TollefsonMK , FrankI , WintersJL , ThapaP , et al. Efficacy and safety of intraoperative tranexamic acid infusion for reducing blood transfusion during open radical cystectomy. Urology2016;92:57-62.">Zaid 2016</a>). </p> </section> </section> <section id="CD015122-sec-0014"> <h3 class="title" id="CD015122-sec-0014">How the intervention might work</h3> <p>The relationship between TXA and urologic surgery is unique due to the fibrinolytic action of urokinase and high concentrations of plasminogen within urine, both of which lead to the breakdown of blood clots. Its antifibrinolytic action with renal excretion counteract urokinase and prevent conversion of urine plasminogen to plasmin, thus reducing clot lysis (<a href="./references#CD015122-bbs2-0033" title="CrescentiA , BorghiG , BignamiE , BertarelliG , LandoniG , CasiraghiGM , et al. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: double blind, randomised, placebo controlled trial. BMJ2011;343:d5701. [DOI: 10.1136/bmj.d5701]">Crescenti 2011</a>; <a href="./references#CD015122-bbs2-0068" title="KumsarS , DirimA , ToksözS , SağlamHS , AdsanO . Tranexamic acid decreases blood loss during transurethral resection of the prostate (TUR-P). Central European Journal of Urology2011;64(3):156-8.">Kumsar 2011</a>; <a href="./references#CD015122-bbs2-0083" title="NielsenJD , GramJ , Holm-NielsenA , FabrinK , JespersenJ . Post-operative blood loss after transurethral prostatectomy is dependent on in situ fibrinolysis. British Journal of Urology1997;80(6):889-93.">Nielsen 1997</a>; <a href="./references#CD015122-bbs2-0091" title="RannikkoA , PétasA , TaariK . Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology2004;64(5):955-8.">Rannikko 2004</a>). Therefore, the antifibrinolytic properties of TXA may offer an effective management strategy in reducing blood loss in PCNL, just as it has served a similar purpose in the fields of trauma, medicine, and surgery, including other urologic procedures. </p> </section> <section id="CD015122-sec-0015"> <h3 class="title" id="CD015122-sec-0015">Why it is important to do this review</h3> <p>A number of studies have suggested that TXA may have a favorable impact on the outcomes of PCNL. This includes several systematic reviews (<a href="./references#CD015122-bbs2-0042" title="FengD , ZhangF , LiuS , HanP , WeiW . Efficacy and safety of the tranexamic acid in reducing blood loss and transfusion requirements during percutaneous nephrolithotomy: a systematic review and meta-analysis of randomized controlled trials. Minerva Urology and Nephrology2020;72(5):579-85.">Feng 2020</a>; <a href="./references#CD015122-bbs2-0079" title="MisraV , GkentzisA . The use of haemostatic agents in percutaneous nephrolithotomy: a systematic review. SN Comprehensive Clinical Medicine2020;2:192-202.">Misra 2020</a>; <a href="./references#CD015122-bbs2-0112" title="WangZ , HeX , BaiY , WangJ . Can tranexamic acid reduce the blood transfusion rate in patients undergoing percutaneous nephrolithotomy? A systematic review and meta-analysis. Journal of International Medical Research2020;48(4):300060520917563.">Wang 2020</a>). However, none of these are of high methodological quality as characterized by an a priori protocol, a focus on patient‐important outcomes and clinically meaningful differences, a comprehensive literature search without consideration of language of publication status, and the application of GRADE for rating the certainty of evidence. This review will provide an evidence‐based assessment of the use of TXA in individuals undergoing PCNL to inform individual patient decision‐making, guidelines and health‐policy makers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015122-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015122-sec-0016"></div> <p>To assess the effects of tranexamic acid; (TXA) in adults with kidney stones undergoing percutaneous nephrolithotomy (PCNL). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015122-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015122-sec-0017"></div> <section id="CD015122-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015122-sec-0019"> <h4 class="title">Types of studies</h4> <p>We included only parallel‐group randomized trials. We included studies regardless of their publication status or language of publication. We did not consider cross‐over or cluster‐randomized controlled trials, since these are not applicable to the clinical question of interest. We also excluded pseudo‐randomized trials (in which treatment allocation took place by alternation) due to the resulting high risk of selection bias. </p> </section> <section id="CD015122-sec-0020"> <h4 class="title">Types of participants</h4> <p>Eligible participants were male and female adults (&gt; 18 years old) with nephrolithiasis treated with PCNL (either performed alone or in addition to retrograde intrarenal surgery (RIRS) during the same operation). </p> <p>When we identified studies in which only a subset of participants was relevant to this review, we included such studies if data were available separately for the relevant subset. </p> </section> <section id="CD015122-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We investigated the following comparisons of experimental intervention versus comparator intervention. We required that concomitant intervention were the same in the experimental and comparator groups to establish fair comparisons. </p> <section id="CD015122-sec-0022"> <h5 class="title">Experimental interventions</h5> <p> <ul id="CD015122-list-0001"> <li> <p>Systemic administration of TXA (i.e. intravenous or oral administration)</p> </li> <li> <p>Topical administration of TXA (i.e. in PCNL irrigant solution)</p> </li> </ul> </p> <p>Although we analyzed the method of TXA administration (systemic versus topical) separately, variations within these administration techniques existed among studies. Examples of variations included differences in TXA dose, frequency of administration, and duration of administration (e.g. intravenous bolus versus intravenous continuous drip). We included any variations within their respective administration methods, and treated these variations as the same intervention within our analysis. </p> </section> <section id="CD015122-sec-0023"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD015122-list-0002"> <li> <p>Placebo or no intervention (i.e. no administration of TXA)</p> </li> </ul> </p> </section> <section id="CD015122-sec-0024"> <h5 class="title">Comparisons</h5> <p> <ul id="CD015122-list-0003"> <li> <p>Systemic administration of TXA versus placebo (or no administration of TXA)</p> </li> <li> <p>Topical administration of TXA (in the irrigation fluid) versus placebo (or no administration of TXA) </p> </li> </ul> </p> </section> </section> <section id="CD015122-sec-0025"> <h4 class="title">Types of outcome measures</h4> <p>We did not use the measurement of the outcomes assessed in this review as an eligibility criterion. </p> <section id="CD015122-sec-0026"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD015122-list-0004"> <li> <p>Blood transfusion (dichotomous outcome)</p> </li> <li> <p>Stone‐freedom (dichotomous outcome)</p> </li> <li> <p>Thromboembolic events (dichotomous outcome)</p> </li> </ul> </p> </section> <section id="CD015122-sec-0027"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD015122-list-0005"> <li> <p>Adverse events (dichotomous outcome)</p> </li> <li> <p>Secondary interventions (dichotomous outcome)</p> </li> <li> <p>Major surgical complications (dichotomous outcome)</p> </li> <li> <p>Minor surgical complications (dichotomous outcome)</p> </li> <li> <p>Unplanned hospitalizations or readmissions (dichotomous outcome)</p> </li> <li> <p>Hospital stay (continuous outcome)</p> </li> </ul> </p> </section> <section id="CD015122-sec-0028"> <h5 class="title">Method and timing of outcome measurement</h5> <section id="CD015122-sec-0029"> <h6 class="title">Blood transfusion</h6> <p> <ul id="CD015122-list-0006"> <li> <p>Administration of at least one unit of packed red blood cells (RBCs) for the management of perioperative blood loss. </p> </li> <li> <p>Outcome was assessed based on individual study reporting within 30 days of the initial PCNL procedure. </p> </li> <li> <p>We considered a ≥ 2% absolute difference in transfusion rates as clinically important.</p> </li> </ul> </p> </section> <section id="CD015122-sec-0030"> <h6 class="title">Stone‐freedom</h6> <p> <ul id="CD015122-list-0007"> <li> <p>Participants with documented clearance of all stones of a given size from the kidney and ureter based on imaging (e.g. non‐contrast computerized tomography (CT), abdominal and pelvic X‐ray, etc.), as determined by the investigators. </p> </li> <li> <p>Outcome was assessed up to 90 days following PCNL.</p> </li> <li> <p>We considered a ≥ 5% absolute difference in stone clearance as clinically important.</p> </li> </ul> </p> </section> <section id="CD015122-sec-0031"> <h6 class="title">Thromboembolic events</h6> <p> <ul id="CD015122-list-0008"> <li> <p>Participants with a diagnosis of a venous thrombosis or pulmonary embolism (PE) (asymptomatic or symptomatic) confirmed by imaging (ultrasound, CT or other), as determined by the investigators. </p> </li> <li> <p>Outcome was assessed up to 90 days following PCNL.</p> </li> <li> <p>We considered a ≥ 2% absolute difference in thromboembolic events as clinically important.</p> </li> </ul> </p> </section> <section id="CD015122-sec-0032"> <h6 class="title">Adverse events</h6> <p> <ul id="CD015122-list-0009"> <li> <p>This outcome comprised adverse events related to the intervention (administration of TXA). Common side effects of TXA administration include nausea and diarrhea (<a href="./references#CD015122-bbs2-0108" title="TengbornL , BlombäckM , BerntorpE . Tranexamic acid – an old drug still going strong and making a revival. Thrombosis Research2015;135(2):231-42.">Tengborn 2015</a>). Rarer, but more severe side effects include hypersensitivity reactions, cerebrovascular infarction, myocardial infarction, acute renal cortical necrosis, and seizure (<a href="./references#CD015122-bbs2-0030" title="CalapaiG , GangemiS , MannucciC , MinciulloPL , CasciaroM , CalapaiF , et al. Systematic review of tranexamic acid adverse reactions. Journal of Pharmacovigilance2015;3(4):1000171. [DOI: 10.4172/2329-6887.1000171]">Calapai 2015</a>). Thromboembolic events, such as pulmonary embolism and deep vein thrombosis (DVT) were not included but were captured as an independent outcome (see above). </p> </li> <li> <p>Outcome was assessed up to 30 days following PCNL.</p> </li> <li> <p>We considered a ≥ 5% absolute difference in adverse events as clinically important.</p> </li> </ul> </p> </section> <section id="CD015122-sec-0033"> <h6 class="title">Secondary interventions</h6> <p> <ul id="CD015122-list-0010"> <li> <p>Unplanned additional procedures or treatments needed to attain successful stone clearance or to treat intraoperative or postoperative complications following completion of the initial procedure. </p> </li> <li> <p>Outcome was assessed up to 90 days following PCNL.</p> </li> <li> <p>We considered a ≥ 5% absolute difference in secondary interventions as clinically important. </p> </li> </ul> </p> </section> <section id="CD015122-sec-0034"> <h6 class="title">Major surgical complications</h6> <p> <ul id="CD015122-list-0011"> <li> <p>Participants developing intraoperative or postoperative complications requiring additional surgical or radiological intervention or complications that are life‐threatening, causing single‐ or multi‐organ dysfunction, or death. </p> </li> <li> <p>Outcome was assessed up to 30 days following PCNL.</p> </li> <li> <p>Outcome was assessed using Clavien‐Dindo classification, and complications categorized as grade III or higher were considered 'major' and included (<a href="./references#CD015122-bbs2-0038" title="DindoD , DemartinesN , ClavienPA . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery2004;240(2):205-13. [PMID: 15273542]">Dindo 2004</a>). If clarification was needed on determination of complication grade, we cross‐referenced the Clavien Score for PCNL (<a href="./references#CD015122-bbs2-0036" title="dela RosetteJJ , OpondoD , DaelsFP , GiustiG , SerranoA , KandasamiSV , et al, CROES PCNL Study Group. Categorisation of complications and validation of the Clavien score for percutaneous nephrolithotomy. European Urology2012;62(2):246-55. [PMID: 22487016]">de la Rosette 2012</a>). </p> </li> <li> <p>We considered a ≥ 2% absolute difference in major complication rate as clinically important. </p> </li> </ul> </p> </section> <section id="CD015122-sec-0035"> <h6 class="title">Minor surgical complications</h6> <p> <ul id="CD015122-list-0012"> <li> <p>Participants with a deviation from the normal postoperative course without the need for surgical or radiological intervention, including wound infections, blood transfusions, and need for total parenteral nutrition. </p> </li> <li> <p>Outcome was assessed up to 30 days following PCNL.</p> </li> <li> <p>Outcome was assessed using Clavien‐Dindo classification, and complications categorized as grade I or II were considered 'minor' and included (<a href="./references#CD015122-bbs2-0038" title="DindoD , DemartinesN , ClavienPA . Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Annals of Surgery2004;240(2):205-13. [PMID: 15273542]">Dindo 2004</a>). If clarification was needed on determination of complication grade, we cross‐referenced the Clavien Score for PCNL (<a href="./references#CD015122-bbs2-0036" title="dela RosetteJJ , OpondoD , DaelsFP , GiustiG , SerranoA , KandasamiSV , et al, CROES PCNL Study Group. Categorisation of complications and validation of the Clavien score for percutaneous nephrolithotomy. European Urology2012;62(2):246-55. [PMID: 22487016]">de la Rosette 2012</a>). </p> </li> <li> <p>We considered a ≥ 5% absolute difference in minor complication rate as clinically important. </p> </li> </ul> </p> </section> <section id="CD015122-sec-0036"> <h6 class="title">Unplanned hospitalizations or readmissions</h6> <p> <ul id="CD015122-list-0013"> <li> <p>Any unplanned hospitalization or readmission to the hospital setting that occurs after a participant is discharged following primary PCNL (and its associated hospital admission if applicable). </p> </li> <li> <p>Outcome was determined if an unplanned hospitalization or readmission in the experimental and control groups occurs up to 30 days following PCNL. </p> </li> <li> <p>We considered a ≥ 2% absolute difference in readmission rate as clinically important.</p> </li> </ul> </p> </section> <section id="CD015122-sec-0037"> <h6 class="title">Hospital stay</h6> <p> <ul id="CD015122-list-0014"> <li> <p>Duration of hospitalization in hours following participant's primary PCNL.</p> </li> <li> <p>Outcome was assessed as hours from admission to discharge after primary PCNL.</p> </li> <li> <p>We considered a ≥ 0.5 day difference as clinically important.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD015122-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed a comprehensive search on 19 May 2021, with no restrictions on the language of publication, country of origin, or publication status. We reran the searches on 16 February 2022, 2 August 2022, and 11 May 2023 within three months prior to anticipated publication of the review. </p> <section id="CD015122-sec-0039"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from inception of each database, using appropriate controlled vocabulary indexing and natural language search terms. </p> <p> <ul id="CD015122-list-0015"> <li> <p>Cochrane Library (via Wiley), including the Cochrane Database of Systematic Reviews (CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL) </p> </li> <li> <p>PubMed, including MEDLINE (via National Center for Biotechnology Information; NCBI)</p> </li> <li> <p>Embase (via Elsevier)</p> </li> <li> <p>Scopus (via Elsevier)</p> </li> <li> <p>Global Index Medicus (via World Health Organization; WHO)</p> </li> </ul> </p> <p>We also searched the following.</p> <p> <ul id="CD015122-list-0016"> <li> <p>ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>) </p> </li> </ul> </p> <p>We did not detect additional relevant keywords during any of the electronic or other searches, and did not modify the electronic search strategies during our repeat search. </p> <p>Our comprehensive search strategies for each respective database are outlined in <a href="./appendices#CD015122-sec-0138">Appendix 1</a>. </p> </section> <section id="CD015122-sec-0040"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially‐eligible trials or ancillary publications by searching the reference lists of retrieved included trials, reviews, meta‐analysis and health technology assessment reports. We contacted study authors of included trials to identify any further studies that we may have missed. We contacted drug/device manufacturers for ongoing or unpublished trials. Abstract proceedings of relevant meetings (such as those of the American Urological Association, European Association of Urology and World Congress of Endourology) were included in the electronic databases and were therefore also captured. </p> </section> </section> <section id="CD015122-sec-0041"> <h3 class="title" id="CD015122-sec-0041">Data collection and analysis</h3> <section id="CD015122-sec-0042"> <h4 class="title">Selection of studies</h4> <p>We used reference management software (EndNote) to identify and remove potential duplicate records. Pairs of review authors (BC, BN, HW, VG, PD) independently scanned the abstract, title, or both, of remaining records retrieved, to determine which studies should be assessed further. Two of the multiple review authors (BC, BN, HW, VG) independently investigated all potentially‐relevant records as full text, mapped records to studies, and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies, in accordance with the criteria for each provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015122-bbs2-0053" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023.. Available from www.training.cochrane.org/handbook..">Higgins 2023_A</a>). We resolved any discrepancies through consensus or recourse to a third review author (PD). If resolution of a disagreement was not possible, we designated the study as 'awaiting classification' and contacted study authors for clarification. We documented reasons for exclusion of studies that may have reasonably been expected to be included in the review in the <a href="./references#CD015122-bbs1-0002" title="">Excluded studies</a> section. We present a PRISMA flow diagram showing the process of study selection in <a href="#CD015122-fig-0001">Figure 1</a> (<a href="./references#CD015122-bbs2-0073" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]">Liberati 2009</a>). </p> <div class="figure" id="CD015122-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) flow diagram." data-id="CD015122-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) flow diagram.</p> </div> </div> </div> </section> <section id="CD015122-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data collection form and pilot tested it ahead of time.</p> <p>For studies that fulfilled inclusion criteria, two of the multiple review authors (BC, BN, HW, VG) independently collected the following information, which we provided in the 'Baseline Characteristics and Demographics of Included Studies' table (<a href="#CD015122-tbl-0003">Table 1</a>) and 'Clinical Characteristics of Included Studies' table (<a href="#CD015122-tbl-0004">Table 2</a>). </p> <div class="table" id="CD015122-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline Characteristics and Demographics of Included Studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study Name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial Period (year to year)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting/Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Description and Total # of Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Male:Female</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean BMI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration of follow up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and Comparators <sup>a</sup> </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Bansal 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jan 2009 to June 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with renal calculi planned to undergo PCNL</p> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>116:84</p> <p>Control</p> <p>109:91</p> <p>Overall</p> <p>225:175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>32.7</p> <p>Control:</p> <p>34.7</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>22.5</p> <p>Control:</p> <p>22.9</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>0.1% tranexamic acid solution (1000 mg in 1 L of normal saline)</p> <p>Control</p> <p>10 mL distilled water (placebo) in 1 L of normal saline</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Batagello 2021</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 May 2016 to 21 May 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 years and older, with complex kidney stones (Guy’s stone score of 3 and 4)</p> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>32:61</p> <p>Control</p> <p>31:65</p> <p>Overall: 63:126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>44</p> <p>Control:</p> <p>45</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>26.4</p> <p>Control: 27.4</p> <p>Overall: Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1g of TXA in 250 mL saline (IV) over 15 mins</p> <p>Control:</p> <p>0.9% NaCl 250 mL (IV) over 15 minutes</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Iskakov 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jan 2013 to June 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Kazakhstan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 patients age 18 to 75 years</p> <p>with nephrolithiasis undergoing PCNL</p> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>35:47</p> <p>Control</p> <p>47:35</p> <p>Overall:</p> <p>82:82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>47.3</p> <p>Control:</p> <p>45.8</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>29.4</p> <p>Control:</p> <p>27.9</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>10 mL TXA to 200 mL saline solution (IV) immediately before surgery</p> <p>Control:</p> <p>No intervention</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Kumar 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jan 2011 to June 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 participants undergoing PCNL for renal stone disease</p> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>58:42</p> <p>Control:</p> <p>54:46</p> <p>Overall:</p> <p>112:88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA: 37.9</p> <p>Control: 39.9</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>68 patients with BMI &lt; 30; 32 patients with BMI &gt; 30</p> <p>Control:</p> <p>73 patients with BMI &lt; 30; 27 patients with BMI &gt; 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimum of 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 gm TXA IV followed by 3 500 mg oral dosages at 8 hr interval</p> <p>Control:</p> <p>Usual care</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Maghsoudi 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Not reported</p> <p>Control:</p> <p>Not reported</p> <p>Overall:</p> <p>185:87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>"Group 2" 44.2</p> <p>"Group 3" 45.5</p> <p>Control:</p> <p>48.7</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>"Group 2" ‐ 15mg/kg TXA injected anesthesia induction and after 12 hours three doses of 500 mg were injected every 8 hours. </p> <p>"Group 3" ‐</p> <p>10mg/kg TXA injected at anesthesia induction and after 12 hours three doses of 250 mg were injected every 8 hours </p> <p>Control:</p> <p>Usual care</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mohammadi 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jan 2014 to Nov 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who underwent PCNL for staghorn calculi</p> <p>(Group 1 = stones &gt; 4mm;</p> <p>Group 2 = stones &lt; 4mm)</p> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1 </p> <p>TXA: 25:5</p> <p>Control: 21:9</p> <p>Group 2 </p> <p>TXA: 21:9</p> <p>Control: 24:6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1 </p> <p>TXA: 42.8</p> <p>Control: 43.6</p> <p>Group 2 </p> <p>TXA: 41.1</p> <p>Control: 41.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1 </p> <p>TXA: 25.7</p> <p>Control: 25.1</p> <p>Group 2 </p> <p>TXA: 23.70</p> <p>Control: 24.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1 g of TXA intravenously for 12 hours until discharge and then orally following discharge for 1 week </p> <p>Control:</p> <p>1 g of normal saline until discharge</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mohammadi Sichani 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sept 2016 to Nov 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 18 years of age, normal functioning contralateral kidney (Serum Cr of 1.5 mg/dL or less) </p> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>45:19</p> <p>Control:</p> <p>44:22</p> <p>Overall:</p> <p>89:41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>45.9</p> <p>Control:</p> <p>45.1</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>24.4</p> <p>Control:</p> <p>25.2</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1 g of TXA (IV) at start of procedure, then 1g q8 hrs for first 48 hrs (max.total dose of 6 g) </p> <p>Control:</p> <p>Saline solution</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mokhtari 2021</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney or upper ureteral stone (&gt; 2 cm at pelvic/upper calices, &gt; 1.5 cm at lower calices), failed ESWL </p> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>28:26</p> <p>Control:</p> <p>30:24</p> <p>Overall:</p> <p>58:50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA: 39.5</p> <p>Control:</p> <p>42.4</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1 g TXA (IV) at start of procedure, 5 mg (PO) q8 hrs for 3 days</p> <p>Control: normal saline, then placebo capsules q8 hrs for 3 days</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rashid 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>March 2017 to Nov 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Iraq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults age &gt; 18 years with renal stones who failed shock wave lithotripsy</p> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control:</p> <p>17:8</p> <p>TXA:</p> <p>16:9</p> <p>Overall:</p> <p>33:17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control:</p> <p>48.9</p> <p>TXA:</p> <p>48.1</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control:</p> <p>26.7</p> <p>TXA:</p> <p>28.6</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1 gm (10 cc) of the TXA 20 minute before surgery</p> <p>Control:</p> <p>10 cc of normal saline injection</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Siddiq 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oct 2015 to April 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 16–75 years of both genders, undergoing PCNL for renal stone size of more than 2 cm </p> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>72:48</p> <p>Control:</p> <p>82:38</p> <p>Overall:</p> <p>154:86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>41</p> <p>Control</p> <p>40</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>25.7</p> <p>Control</p> <p>26.2</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Injection 1 gram of TXA</p> <p>Control:</p> <p>Injection 1 gram of placebo</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>BMI:</b> body mass index; <b>IV:</b> invtravenous(ly); <b>PCNL:</b> percutaneous nephrolithotomy; <b>PO:</b> per oral; <b>TXA:</b> tranexamic acid </p> <p><sup>a</sup> Intervention and Comparators = route and dose of TXA vs placebo (or usual care, etc.) </p> </div> </div> <div class="table" id="CD015122-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Clinical Characteristics of Included Studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study Name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean Stone Size</b> </p> <p><b>(mm)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Stone location</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Access Size <sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Access</b> </p> <p><b>Location <sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of access sites <sup>c</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Stone Surface area ± SD (cm<sup>2</sup>)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Bansal 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Staghorn 22</p> <p>Control:</p> <p>Staghorn 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>2.79 (± 2.12)</p> <p>Control</p> <p>2.91 (± 2.05)</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Batagello 2021</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>46.8</p> <p>Control:</p> <p>49.3</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 24 Fr for control group</p> <p>and TXA group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Supra 24</p> <p>Infra 69</p> <p>Control:</p> <p>Supra 18</p> <p>Infra 78</p> <p>Overall:</p> <p>Supra 42</p> <p>Infra 147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 72</p> <p>Multiple 21</p> <p>Control:</p> <p>Single 67 Multiple 29</p> <p>Overall:</p> <p>Single 139</p> <p>Multiple 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Iskakov 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Pelvis 21</p> <p>Lower calyx 6</p> <p>Pelvis+calyx 6</p> <p>Proximal ureter 4</p> <p>Upper calyx 2</p> <p>Middle calyx 0</p> <p>Staghorn 43</p> <p>Control:</p> <p>Pelvis 28</p> <p>Lower calyx 3</p> <p>Pelvis+calyx 4</p> <p>Proximal ureter 7</p> <p>Upper calyx 0</p> <p>Middle calyx 3</p> <p>Staghorn 37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 24 Fr for control group</p> <p>and TXA group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 82</p> <p>Multiple 0</p> <p>Control:</p> <p>Single 82</p> <p>Multiple 0</p> <p>Overall:</p> <p>Single 82</p> <p>Multiple 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>6.62 (± 0.67)</p> <p>Control:</p> <p>5.22 (± 0.46)</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Kumar 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Staghorn 16</p> <p>Control:</p> <p>Staghorn 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 24 Fr for control group</p> <p>and TXA group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 80</p> <p>Mulitple 20</p> <p>Control:</p> <p>Single 76</p> <p>Multiple 24</p> <p>Overall:</p> <p>Single 156</p> <p>Multiple 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>3.79 (± 3.46)</p> <p>Control:</p> <p>3.73 (± 2.99)</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Maghsoudi 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>"Group 2" 5.89</p> <p>"Group 3" 5.92</p> <p>Control:</p> <p>5.95</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mohammadi 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 patients with stones &gt; 40 mm (Group 1)</p> <p>60 patients with stones &lt; 40 mm</p> <p>(Group 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mohammadi Sichani 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 24 Fr for control group</p> <p>and TXA group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 37</p> <p>Multiple 27</p> <p>Control:</p> <p>Single 46</p> <p>Multiple 20</p> <p>Overall:</p> <p>Single 83</p> <p>Multiple 47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>3.45 (± 1.52)</p> <p>Control:</p> <p>3.93 (± 1.76)</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mokhtari 2021</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>36.2</p> <p>Control: 35.8</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Upper calyx 6</p> <p>Pelvis 0</p> <p>Lower calyx 37</p> <p>Control:</p> <p>Upper calyx 8</p> <p>Pelvis 0</p> <p>Lower calyx 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rashid 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 21</p> <p>Multiple 4</p> <p>Control:</p> <p>Single 23</p> <p>Multiple 2</p> <p>Overall:</p> <p>Single 44</p> <p>Multiple 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Siddiq 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>21.5</p> <p>Control:</p> <p>31.8</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Upper Calyx 24</p> <p>Pelvis 30</p> <p>Lower Calyx 51</p> <p>Multiple Calyces 15</p> <p>Control:</p> <p>Upper Calyx 26</p> <p>Pelvis 31</p> <p>Lower Calyx 49</p> <p>Multiple Calyces 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>≥ 24 Fr 107</p> <p>&lt; 24 Fr 13</p> <p>Control:</p> <p>≥ 24 Fr</p> <p>109</p> <p>&lt; 24 Fr</p> <p>11</p> <p>Overall:</p> <p>≥ 24 Fr</p> <p>216</p> <p>&lt; 24 Fr</p> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Supra 54</p> <p>Infra 66</p> <p>Control:</p> <p>Supra 57</p> <p>Infra 63</p> <p>Overall:</p> <p>Supra 111</p> <p>Infra 129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>Fr:</b> French gauge; <b>SD:</b> standard deviation; <b>TXA:</b> tranexamic acid </p> <p><sup>a</sup> Access size = ≥ 24 Fr (#) vs &lt; 24 Fr (#) </p> <p><sup>b</sup> Access location = supracostal vs infracostal </p> <p><sup>c</sup> Number of access sites = single (#) / multiple (#) </p> </div> </div> <p> <ul id="CD015122-list-0017"> <li> <p>Study design</p> </li> <li> <p>Study dates (if dates were not available then this was reported as such)</p> </li> <li> <p>Study settings and country</p> </li> <li> <p>Participant inclusion and exclusion criteria</p> </li> <li> <p>Participant details, baseline demographics (e.g. age, gender, body mass index (BMI), stone size, stone location, access location, access size) </p> </li> <li> <p>The number of participants by study and by study arm</p> </li> <li> <p>Details of relevant experimental (such as TXA dose, route, frequency, and duration) and comparator interventions (placebo or no TXA administration) </p> </li> <li> <p>Definitions of relevant outcomes (see above), and method and timing of outcome measurement (see above), as well as any relevant subgroups (number of access sites, location of access site, access sheath size, stone size, stone location) </p> </li> <li> <p>Study funding sources</p> </li> <li> <p>Declarations of interest by primary investigators</p> </li> </ul> </p> <p>We extracted outcome data relevant to this Cochrane Review as needed for calculation of summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain numbers of events and totals for population of a 2 × 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and standard deviations (SDs) or data necessary to calculate this information. </p> <p>We resolved any disagreements by discussion, or, if required, by consultation with a third review author (PD). </p> <p>We provided information, including trial identifier, about potentially relevant ongoing studies in the <a href="./references#CD015122-sec-0156" title="">Characteristics of ongoing studies</a> section. </p> <p>We attempted to contact authors of included studies to obtain key missing data as needed. </p> <section id="CD015122-sec-0044"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>For duplicate publications, such as companion documents or multiple reports of a primary study, we maximized yield of information by mapping all publications to unique studies and collating all available data. We used the most complete dataset aggregated across all known publications. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD015122-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two of the multiple review authors (BC, BN, HW, VG) assessed the risk of bias of each included study independently. We resolved disagreements by consensus or by consultation with a third review author (PD). </p> <p>We assessed risk of bias using Cochrane's risk of bias assessment tool RoB 1 (<a href="./references#CD015122-bbs2-0054" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.">Higgins 2023_B</a>). We assessed the following domains. </p> <p> <ul id="CD015122-list-0018"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment for objective outcomes (detection bias)</p> </li> <li> <p>Blinding of outcome assessment for subjective outcomes (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other sources of bias</p> </li> </ul> </p> <p>We judged risk of bias domains as 'low risk', 'high risk' or 'unclear risk', and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015122-bbs2-0054" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.">Higgins 2023_B</a>). We present a risk of bias summary figure to illustrate these findings in <a href="#CD015122-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD015122-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD015122-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <p>For performance bias (blinding of participants and personnel) and detection bias (blinding of outcome assessment), we evaluated the risk of bias separately for each outcome, and we grouped outcomes according to whether measured subjectively or objectively when reporting our findings in the risk of bias tables. </p> <p> <ul id="CD015122-list-0019"> <li> <p>For performance bias, we have determined all outcomes as equally susceptible to bias and therefore assessed them as one group. </p> </li> <li> <p>For detection bias, we grouped the following outcomes as:</p> <ul id="CD015122-list-0020"> <li> <p>investigator‐assessed, subjective: stone‐freedom, thromboembolic event, adverse event, minor surgical complication; </p> </li> <li> <p>investigator‐assessed, objective: blood transfusion, secondary intervention, major surgical complication, unplanned readmissions, hospital stay. </p> </li> </ul> </li> </ul> </p> <p>We also assessed attrition bias (incomplete outcome data) on an outcome‐specific basis, and present the judgment for each outcome separately when reporting our findings in the risk of bias tables unless the resulting ratings are identical. We considered an attrition rate of &lt; 10% in any trial arm as low risk of bias, 10% to 19% as unclear risk of bias, and ≥ 20% as high risk of bias. </p> <p>We assessed risk of selective reporting bias on a per‐study basis. If no a priori protocol was available, we judged the risk of bias as unclear. </p> <p>We used the 'other risk of bias' category to identify any other potential issues specific to its clinical question not captured in the above risk of bias categories. </p> <p>We further summarized the risk of bias across domains for each outcome in each included study, as well as across studies and domains for each outcome, in accordance with the approach for summary assessments of the risk of bias presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015122-bbs2-0054" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.">Higgins 2023_B</a>). </p> </section> <section id="CD015122-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). We expressed continuous data as mean differences (MDs) with 95% CIs unless different studies used different measures to assess the same outcome, in which case we expressed data as standardized mean differences (SMDs) with 95% CIs. </p> </section> <section id="CD015122-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. We excluded cross‐over or cluster‐randomized controlled since these are not applicable to the clinical question of interest. </p> <p>If studies with multiple treatment arms were identified, we addressed these in accordance with the approach for inclusion of multiple groups (as for <a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a>; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>) from one study as presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015122-bbs2-0055" title="HigginsJPT , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023).. Available from www.training.cochrane.org/handbook..">Higgins 2023_C</a>). </p> </section> <section id="CD015122-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We sought to obtain missing data from study authors, if feasible, and performed intention‐to‐treat (ITT) analyses when data were available; otherwise, we performed available‐case analyses. We investigated attrition rates, e.g. dropouts, losses to follow‐up and withdrawals, and critically appraised issues of missing data. We did not impute missing data. </p> </section> <section id="CD015122-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of excessive heterogeneity unexplained by subgroup analyses, we reported outcome results as the pooled effect estimate in a meta‐analysis, but provided a narrative description of the results of each study. </p> <p>We identified heterogeneity (inconsistency) through visual inspection of the forest plots to assess the amount of overlap of CIs, and the I<sup>2</sup> statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD015122-bbs2-0051" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [DOI: 10.1002/sim.1186]">Higgins 2002</a>; <a href="./references#CD015122-bbs2-0052" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. British Medical Journal (Clinical Research Edition)2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557]">Higgins 2003</a>); we interpreted the I<sup>2</sup> statistic as follows (<a href="./references#CD015122-bbs2-0037" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022.. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>): </p> <p> <ul id="CD015122-list-0021"> <li> <p>0% to 40%: may not be important;</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When we found heterogeneity, we attempted to determine possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD015122-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess for selective outcome reporting.</p> <p>Per our published protocol, funnel plots would be used to assess small study effects if 10 or more studies investigating a particular outcome were identified. Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence, bias of small trials) and publication bias. We therefore interpreted results carefully. However, we did not find 10 or more studies investigating a particular outcome, so funnel plots were not utilized per the a priori threshold. </p> </section> <section id="CD015122-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We summarized data using a random‐effects model. We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. In addition, we performed statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015122-bbs2-0053" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023.. Available from www.training.cochrane.org/handbook..">Higgins 2023_A</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method; for continuous outcomes, we used the inverse variance method; and for time‐to‐event outcomes, we used the generic inverse variance method. We used <a href="./references#CD015122-bbs2-0093" title="Review Manager 5 (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a> software to perform analyses. </p> <p>If meta‐analysis was not possible, we would have performed a narrative synthesis of quantitative intervention effect data via the Synthesis Without Meta‐analysis (SWiM) guideline (<a href="./references#CD015122-bbs2-0031" title="CampbellM , McKenzieJE , SowdenA , KatikireddiSV , BrennanSE , EllisS , et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ2020;368:l6890.">Campbell 2020</a>). The SWiM approach incorporates the following nine reporting items. </p> <p> <ol id="CD015122-list-0022"> <li> <p>Grouping studies for synthesis</p> </li> <li> <p>Describe the standardized metric and transformation methods used</p> </li> <li> <p>Describe the synthesis methods</p> </li> <li> <p>Criteria used to prioritize results for summary and synthesis</p> </li> <li> <p>Investigation of heterogeneity in reported effects</p> </li> <li> <p>Certainty of evidence</p> </li> <li> <p>Data presentation methods</p> </li> <li> <p>Reporting results</p> </li> <li> <p>Limitations of the synthesis</p> </li> </ol> </p> </section> <section id="CD015122-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity (supporting rationale below), and planned to carry out subgroup analyses with investigation of interactions. </p> <p> <ul id="CD015122-list-0023"> <li> <p>Single (one access tract) versus multiple (two or more access tracts) PCNL access sites </p> </li> <li> <p>PCNL access targeted calyx (lower, middle, upper)</p> </li> <li> <p>Standard versus mini‐PCNL access sheath size (&lt; 24 Fr versus ≥ 24 Fr sheath)</p> </li> <li> <p>Stone size (≤ 2 cm versus &gt; 2 cm)</p> </li> </ul> </p> <p>Multiple percutaneous access sites with subsequent dilation through renal parenchyma would conceivably put a participant at risk for increased blood loss or other complications. Numerous retrospective cohort studies have shown that multiple PCNL access sites are a risk factor for increased bleeding (<a href="./references#CD015122-bbs2-0023" title="AkmanT , BinbayM , SariE , YurukE , TepelerA , AkcayM , et al. Factors affecting bleeding during percutaneous nephrolithotomy: single surgeon experience. Journal of Endourology2011;25(2):327-33.">Akman 2011</a>; <a href="./references#CD015122-bbs2-0024" title="AroraAM , PawarPW , TamhankarAS , SawantAS , MundheST , PatilSR . Predictors for severe hemorrhage requiring angioembolization post percutaneous nephrolithotomy: a single-center experience over 3 years. Urology Annals2019;11(2):180-6.">Arora 2019</a>). Another retrospective cohort study also found an association between postoperative fevers and multiple access tracts (<a href="./references#CD015122-bbs2-0027" title="BansalSS , PawarPW , SawantAS , TamhankarAS , PatilSR , KasatGV . Predictive factors for fever and sepsis following percutaneous nephrolithotomy: a review of 580 patients. Urology Annals2017;9(3):230-3.">Bansal 2017</a>). </p> <p>Access location, which is often determined by stone location, has been shown to have effect on stone‐free rates as well as overall surgical complications rates (<a href="./references#CD015122-bbs2-0107" title="TefekliA , EsenT , OlbertPJ , TolleyD , NadlerRB , SunYH , et al. Isolated upper pole access in percutaneous nephrolithotomy: a large-scale analysis from the CROES percutaneous nephrolithotomy global study. Journal of Urology2013;189(2):568-73.">Tefekli 2013</a>). </p> <p>The size of access sheath used for PCNL corresponds to the size of tract dilation through the renal parenchyma. Larger sheaths requiring larger tracts could theoretically increase bleeding or complication rates, or both. Two systematic reviews and meta‐analyzes revealed that, in comparison to standard PCNL, mini‐PCNL with its smaller access sheath has reduced blood loss or a lower rate of blood transfusion (<a href="./references#CD015122-bbs2-0058" title="JiaoB , LuoZ , HuangT , ZhangG , YuJ . A systematic review and meta-analysis of minimally invasive vs. standard percutaneous nephrolithotomy in the surgical management of renal stones. Experimental and Therapeutic Medicine2021;21(3):213.">Jiao 2021</a>; <a href="./references#CD015122-bbs2-0095" title="RuhayelY , TepelerA , DabestaniS , MacLennanS , PetrikA , SaricaK , et al. Tract sizes in miniaturized percutaneous nephrolithotomy: a systematic review from the European Association of Urology Urolithiasis Guidelines Panel. European Urology2017;72(2):220-35. [PMID: 28237786]">Ruhayel 2017</a>; <a href="./references#CD015122-bbs2-0100" title="SharmaG , SharmaA , DevanaSK , SinghSK . Mini versus standard percutaneous nephrolithotomy for the management of renal stone disease: systematic review and meta-analysis of randomized controlled trials. European Urology Focus2021;21:00194-2.">Sharma 2021</a>). Mini‐PCNL has also been shown to have a lower complication rate than standard PCNL (<a href="./references#CD015122-bbs2-0100" title="SharmaG , SharmaA , DevanaSK , SinghSK . Mini versus standard percutaneous nephrolithotomy for the management of renal stone disease: systematic review and meta-analysis of randomized controlled trials. European Urology Focus2021;21:00194-2.">Sharma 2021</a>). </p> <p>Larger stones may require longer operative time or additional percutaneous access sites, both of which may have an effect on blood loss or surgical complications. For example, stone size has been shown to be a predictive factor for vascular complications following PCNL (<a href="./references#CD015122-bbs2-0102" title="SrivastavaA , SinghKJ , SuriA , DubeyD , KumarA , KapoorR , et al. Vascular complications after percutaneous nephrolithotomy: are there any predictive factors?Urology2005;66(1):38-40.">Srivastava 2005</a>). </p> <p>We used the test for subgroup differences in <a href="./references#CD015122-bbs2-0093" title="Review Manager 5 (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a> to compare subgroup analyzes. </p> </section> <section id="CD015122-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses in order to explore the influence of the following factors (when applicable) on effect sizes. </p> <p> <ul id="CD015122-list-0024"> <li> <p>Restricting the analysis by taking into account risk of bias, by excluding studies at 'high risk' or 'unclear risk'. </p> </li> <li> <p>Restricting the analysis to studies using a definition of stone‐freedom of 2 mm or less. </p> </li> </ul> </p> </section> <section id="CD015122-sec-0054"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We developed two summary of findings tables: (i) systemic administration of TXA versus placebo (or no administration of TXA), and (ii) topical administration of TXA (in the irrigation fluid) versus placebo (or no administration of TXA). </p> <p>We presented the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account five criteria not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias), but also to external validity (directness of results) (<a href="./references#CD015122-bbs2-0047" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Schünemann HJ et al. GRADE: what is "quality of evidence" and why is it important to clinicians?British Medical Journal (Clinical Research Edition)2008;336(7651):995-8. [DOI: 10.1136/bmj.39490.551019.BE]'>Guyatt 2008</a>)<i>.</i> For each comparison, two of the multiple review authors (BC, BN, HW, VG) independently rated the certainty of evidence for each outcome as 'high', 'moderate', 'low', or 'very low' using <a href="./references#CD015122-bbs2-0046" title="GRADEpro GDT. Version accessed after 14 February 2022. Hamilton (ON): McMaster University (developed by Evidence Prime), 2021. Available at gradepro.org.">GRADEpro GDT</a>. We resolved any discrepancies by consensus, or, if needed, by arbitration by a third review author (PD). For each comparison, we presented a summary of the evidence for the main outcomes in their respective summary of findings tables (<a href="./full#CD015122-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD015122-tbl-0002">summary of findings Table 2</a>), which provide key information about the best estimate of the magnitude of the effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome (<a href="./references#CD015122-bbs2-0048" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [DOI: 10.1016/j.jclinepi.2010.04.026]">Guyatt 2011</a>; <a href="./references#CD015122-bbs2-0097" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , Guyatt GH. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023.. Available from www.training.cochrane.org/handbook..">Schünemann 2023</a>). </p> <section id="CD015122-sec-0055"> <h5 class="title">Main outcomes for summary of findings tables</h5> <p>We presented summary of findings tables reporting the following outcomes, listed according to priority. </p> <p> <ol id="CD015122-list-0025"> <li> <p>Blood transfusions (within 30 days of the initial PCNL procedure)</p> </li> <li> <p>Stone‐freedom (up to 90 days following PCNL)</p> </li> <li> <p>Thromboembolic events (up to 90 days following PCNL)</p> </li> <li> <p>Adverse events (up to 30 days following PCNL)</p> </li> <li> <p>Secondary Interventions (up to 90 days following PCNL)</p> </li> <li> <p>Major surgical complications (up to 30 days following PCNL)</p> </li> <li> <p>Minor surgical complications (up to 30 days following PCNL)</p> </li> <li> <p>Unplanned hospitalizations or readmissions (up to 30 days following PCNL)</p> </li> <li> <p>Hospital length of stay (after primary PCNL)</p> </li> </ol> </p> <p>In accordance with GRADE guidance (<a href="./references#CD015122-bbs2-0049" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , BrozekJ , NorrisS , MeerpohlJ , DjulbegovicB , Alonso-CoelloP , PostPN , BusseJW , GlasziouP , ChristensenR , SchunemannHJ . GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol2013;66(2):158-72.">Guyatt 2013</a>), we derived the baseline risk use to assess absolute effect size estimates from a large observational, and globally representative study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>) by the Clinical Research Office of the Endourological Society (CROES) PCNL Study Group. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015122-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015122-sec-0056"></div> <section id="CD015122-sec-0057"> <h3 class="title">Description of studies</h3> <p>We completed a comprehensive literature search that yielded 157 references, including seven references from trial registries. We also identified two additional studies cited by other systematic reviews (<a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>) for a total of 159 references. </p> <section id="CD015122-sec-0058"> <h4 class="title">Results of the search</h4> <p>After duplicates were removed, we screened titles and abstracts of 76 records and excluded 55 records. We screened a total of 21 full‐text records and excluded six records. A total of 15 records were qualitatively assessed. Five of these studies were determined to be ongoing; therefore, 10 studies were ultimately included in the quantitative synthesis and meta‐analysis. The details of the literature search are outlined in the PRISMA flowchart (<a href="#CD015122-fig-0001">Figure 1</a>). </p> </section> <section id="CD015122-sec-0059"> <h4 class="title">Included studies</h4> <p>We present details of the included studies in the dedicated section below (<a href="./references#CD015122-bbs1-0001" title="">Included studies</a>). A summary of these studies is also presented within the Baseline Characteristics and Demographics of Included Studies table (<a href="#CD015122-tbl-0003">Table 1</a>). Pertinent clinical aspects of these studies are presented in the Clinical Characteristics of Included Studies table (<a href="#CD015122-tbl-0004">Table 2</a>). </p> <section id="CD015122-sec-0060"> <h5 class="title"><i>S</i>ource of data </h5> <p>We included nine studies published in full‐text and one as an abstract proceeding (<a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a> &amp; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>). The Maghsoudi 2018 study was a single study divided into two separate studies (<a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a>; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>) for the sake of analysis as it consisted of three arms including one control arm ("Group 1") and two intervention arms with differing dose regimens of systemic TXA ("Group 2" and "Group 3"). This separation into two studies for our analysis therefore required dividing its control group into two nearly equivalent cohorts, each matching with one of the respective TXA arms as defined by the study. The division of this study for our analysis was performed in accordance with methods outlined by the Cochrane Handbook of Systematic Reviews of Interventions (<a href="./references#CD015122-bbs2-0053" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023.. Available from www.training.cochrane.org/handbook..">Higgins 2023_A</a>). All studies were published in English. We attempted to contact all corresponding authors of included trials to obtain additional information on study methodology and results where appropriate. We received a reply from very few authors and no unpublished data are included in our analysis. Details of any communication are provided in the "Notes" section of the <a href="./references#CD015122-sec-0154" title="">Characteristics of included studies</a>. </p> </section> <section id="CD015122-sec-0061"> <h5 class="title"><i>S</i>tudy design and settings </h5> <p>We included all parallel RCTs. Two studies were described as "double‐blind" (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>), six as at least partial blinding (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>), and two studies did not mention blinding (<a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a> &amp; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>). </p> <p>The majority of studies were performed in India and Middle Eastern countries, including Iran, Iraq, and Pakistan. A single study was performed in Brazil (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>) and Kazakhstan (<a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>). All studies were carried out at a single center. The studies were performed from January 2011 to May 2019. </p> </section> <section id="CD015122-sec-0062"> <h5 class="title">Participan<i>ts</i> </h5> <p>We included 1883 randomized participants, of whom 1873 completed the trials. The average age of participants was between 32.7 and 48.9 years. </p> <p>Stone sizes were reported in centimeters as stone surface area and/or stone volume. The average stone surface area ranged from 3.45 to 6.62 cm<sup>2</sup>. The stone location was reported in three studies (<a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>). Four studies described presence of staghorn calculi (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>). One study reported stone composition (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>), describing calcium oxalate, calcium phosphate, cystine, struvite and uric acid stones. </p> </section> <section id="CD015122-sec-0063"> <h5 class="title"><i>I</i>nterventions, comparators, and comparisons </h5> <p>Percutaneous access tract size was reported as ≥ 24 Fr in four studies (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>); only one study reported using access tract size &lt; 24 Fr in select cases (<a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>). The remaining four studies did not report percutaneous access tract size. Two studies reported targeted calyx as supracostal or infracostal (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>). Seven studies reported using both a single and multi‐tract approach dependent on stone complexity (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>). Nine studies examined systemic administration of TXA, including one study that compared two different systemic dosing regimens (<a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a> &amp; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>). The two groups within this study were analyzed separately by dividing the control group into two nearly equivalent groups for comparison (as noted above in "Source of data" subsection). A single study investigated topical TXA administered via the irrigant solution during PCNL (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>). </p> <section id="CD015122-sec-0064"> <h6 class="title">Outcomes</h6> <p>We identified the primary outcome of blood transfusion in nine studies (<a href="./references#CD015122-fig-0003" title="">Analysis 1.1</a>; <a href="./references#CD015122-fig-0029" title="">Analysis 2.1</a>). Of the remaining primary outcomes, five studies reported on stone‐free rate (<a href="./references#CD015122-fig-0004" title="">Analysis 1.2</a>; <a href="./references#CD015122-fig-0030" title="">Analysis 2.2</a>) and six reported major surgical complications (<a href="./references#CD015122-fig-0008" title="">Analysis 1.6</a>; <a href="./references#CD015122-fig-0033" title="">Analysis 2.5</a>). With regard to our secondary outcomes, seven studies reported data on hospital length of stay (<a href="./references#CD015122-fig-0011" title="">Analysis 1.9</a>; <a href="./references#CD015122-fig-0035" title="">Analysis 2.7</a>) and thromboembolic events (<a href="./references#CD015122-fig-0005" title="">Analysis 1.3</a>; <a href="./references#CD015122-fig-0031" title="">Analysis 2.3</a>). Between three and six studies reported adverse events, minor surgical complications, and secondary interventions (<a href="./references#CD015122-fig-0006" title="">Analysis 1.4</a>; <a href="./references#CD015122-fig-0007" title="">Analysis 1.5</a>; <a href="./references#CD015122-fig-0009" title="">Analysis 1.7</a>; <a href="./references#CD015122-fig-0032" title="">Analysis 2.4</a>; <a href="./references#CD015122-fig-0034" title="">Analysis 2.6</a>). Only a single study reported unplanned hospitalizations (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-fig-0010" title="">Analysis 1.8</a>). </p> </section> <section id="CD015122-sec-0065"> <h6 class="title">Funding sources and conflicts of interest</h6> <p>Four studies reported funding sources from research grants or hospital departments (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>). One study reported funding from a pharmaceutical company (<a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>). The remaining studies did not report a funding source. No conflicts of interest were reported for all 10 studies. </p> </section> </section> </section> <section id="CD015122-sec-0066"> <h4 class="title">Excluded studies</h4> <p>After a full text review of 21 references, we excluded six studies due to incorrect study design or an inability to locate the study (<a href="./references#CD015122-bbs2-0012" title="Cauni, V, M, V, B, C R, D, M D, B, I. The use of tranexamic acid for preventing hemorrhagic complications during percutaneous nephrolithotomy. European Urology, Supplements2017;16(11):e2972. [DOI: 10.1089/end.2021.0792]">Cauni 2017</a>; <a href="./references#CD015122-bbs2-0013" title="ChoudhuryS , DuttaA , PalDK . Comparison of efficacy of tranexamic acid irrigation versus intravenous injection for preventing blood loss in percutaneous nephrolithotomy. Journal of Clinical Urology December 1, 2021;0:0. [DOI: 10.1177/20514158211059634]">Choudry 2021</a>; <a href="./references#CD015122-bbs2-0014" title="IRCT20171128037664N1. Effect of injection of transamine amine in reducing bleeding. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20171128037664N12018;N/A:N/A. ">IRCT20171128037664N1 2018</a>; <a href="./references#CD015122-bbs2-0015" title="IRCT20180625040232N4. The effects of tranexamic acid on bleeding control. https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20180625040232N42020;N/A:N/A. ">IRCT20180625040232N4 2020</a>; <a href="./references#CD015122-bbs2-0016" title="SafanAM , SamirM , SaeedAM , FaragAS . Effect of high dose tranexamic acid and etamsylate in reducing blood loss during trans-urethral resection of prostate, bladder tumours and percutaneous nephrolithotomy. QJM: An International Journal of Medicine2020;113(1):i261-2. [DOI: 10.1093/qjmed/hcaa070.017]">Safan 2020</a>; <a href="./references#CD015122-bbs2-0017" title="TCTR20200612002. Prospective randomized controlled trial to evaluate effectiveness of tranexamic acid irrigation on perioperative blood loss during percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=TCTR202006120022020;N/A:N/A. ">TCTR20200612002 2020</a>). For additional details, please refer to the <a href="#CD015122-sec-0066">Excluded studies</a> section below. </p> <section id="CD015122-sec-0067"> <h5 class="title">Ongoing studies</h5> <p>We identified five ongoing trials that met inclusion criteria but have yet to report sufficient data (<a href="./references#CD015122-bbs2-0018" title="VincentP . A clinical trial to study the benefits of a drug Tranexamic acid in patients undergoing keyhole surgery for renal stones called percutaneous nephrolithotomy [A Prospective Randomized Controlled Trial Comparing the efficacy of Tranexamic acid in reducing the blood loss during PCNL]. http://www.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/01/0113742018;N/A:N/A. [CTRI/2018/01/011374]">CTRI2018/01/011374 2018</a>; <a href="./references#CD015122-bbs2-0019" title="FarshidS , RezvankhahV , AhmadianN , SadriM . The effect of topical tranexamic acid on postoperative hemoglobin level in patients undergoing PCNL. In: Journal of Endourology. Supplement 1 edition. Vol. 35. October 2021:A40. [DOI: 10.1089/end.2021.35001.abstracts]">Farshid 2021</a>; <a href="./references#CD015122-bbs2-0020" title="Comparative study of the hemostatic effect of transamin on percutaneous nephrolithotomy surgery. Ongoing study. 04/01/2021. Contact author for more information.">IRCT20200526047576N1 2021</a>; <a href="./references#CD015122-bbs2-0021" title="Efficacy of tranexamic acid on blood loss during percutaneous nephrolithotomy. A double-blind, placebo-controlled randomized clinical trial. Ongoing study. 09/01/2019. Contact author for more information.">NCT04367155 2019</a>; <a href="./references#CD015122-bbs2-0022" title="Prospective randomized controlled trial to evaluate the effect of tranexamic acid in irrigant solution on perioperative blood loss during mini-percutaneous nephrolithotomy. Ongoing study. 10/21/2021. Contact author for more information.">TCTR20211021003 2021</a>); therefore, these studies were excluded from our quantitative synthesis and meta‐analysis. Further details regarding these studies are outlined in the <a href="./references#CD015122-bbs1-0003" title="">Ongoing studies</a> section below. </p> </section> <section id="CD015122-sec-0068"> <h5 class="title">Studies awaiting classification</h5> <p>There were no studies identified that are currently awaiting classification.</p> </section> </section> </section> <section id="CD015122-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias was assessed using the following domains (as summarized in <a href="#CD015122-fig-0002">Figure 2</a> with further details outlined within the <a href="./references#CD015122-sec-0154" title="">Characteristics of included studies</a> section): </p> <section id="CD015122-sec-0070"> <h4 class="title">Allocation</h4> <p>Five of the included studies (<a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a> &amp; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) either did not report or did not adequately describe the method of random sequence generation and were therefore rated as unclear risk of bias. </p> <p>For allocation concealment, more than half (seven out of 10) of the included studies were rated as unclear risk of bias for not reporting whether allocation concealment took place (<a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a>; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>), or not adequately describing how their allocation concealment method would safeguard against selection bias (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>). The remaining three studies were rated as low risk for selection bias (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>). </p> </section> <section id="CD015122-sec-0071"> <h4 class="title">Blinding</h4> <p>For performance bias, we assessed the blinding of the participants and the personnel. As per our protocol, we determined all outcomes as equally susceptible to bias and assessed them as one group. Seven out of the ten10 studies (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a> &amp; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>) were rated as unclear risk for performance bias for failing to explicitly describe use of blinding. Two studies (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) were rated as low risk for performance bias, while one study (<a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>) was rated as high risk for performance bias as some personnel were not blinded and blinding was discontinued if potential adverse effects attributable to TXA occurred. </p> <p>For detection bias, the outcomes were grouped as objective or subjective. For the objective outcome domain, blinding of outcome assessors was not relevant. Therefore, all the studies were rated as low risk for detection bias for objective outcomes. In the case of subjective outcomes, the majority (seven out of 10) of the included studies (<a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a> &amp; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) were rated as unclear risk for detection bias usually because it was unclear if or how the outcome assessors were blinded. The remaining three studies (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>) were rated as low risk for detection bias. </p> </section> <section id="CD015122-sec-0072"> <h4 class="title">Incomplete outcome data</h4> <p>For attrition bias, each outcome was assessed individually, but we collapsed reporting as judgments for all the outcomes were identical. Nine studies (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) were rated as low risk for attrition bias with attrition rates of less than 10% in both treatment arms; while a single study (<a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a> &amp; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>) were rated as unclear risk for attrition bias as there was either a conclusion stated without supporting published data or unequal attrition between the control and intervention groups without explanation or justification. </p> </section> <section id="CD015122-sec-0073"> <h4 class="title">Selective reporting</h4> <p>We assessed selective reporting on a per‐study basis. Only one study (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>) was rated as low risk of selective reporting bias as the study had <i>a priori</i> protocol and the study design, primary outcomes, and secondary outcomes in the published study were in accordance with the <i>a priori</i> protocol. Seven out of the ten studies (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a> &amp; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) were rated as unclear risk of reporting bias because there was either no <i>a priori</i> protocol or some differences were found between the published study and its protocol. Two studies (<a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>) were rated as high risk for reporting bias because of unclear and/or absent reporting of expected outcomes as well as discrepancies between the outcomes described in published protocol and those in the final manuscript. </p> </section> <section id="CD015122-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>All studies were rated as low risk for other bias except one study (<a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a> &amp; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>), which was rated as unclear risk for other bias due to the overall lack in information available regarding its methods and results as it was published in the form of an abstract proceeding. </p> </section> </section> <section id="CD015122-sec-0075"> <h3 class="title" id="CD015122-sec-0075">Effects of interventions</h3> <p>See: <a href="./full#CD015122-tbl-0001"><b>Summary of findings 1</b> Systemic TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</a>; <a href="./full#CD015122-tbl-0002"><b>Summary of findings 2</b> Topical TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</a> </p> <p>See: <a href="./full#CD015122-tbl-0001">summary of findings Table 1</a> ‐ Systemic TXA compared to no TXA (placebo or usual care) for percutaneous nephrolithotomy. </p> <p>See: <a href="./full#CD015122-tbl-0002">summary of findings Table 2</a> ‐ Topical TXA compared to no TXA (placebo or usual care) for percutaneous nephrolithotomy. </p> <section id="CD015122-sec-0076"> <h4 class="title">Systemic TXA compared to no TXA (placebo or usual care)</h4> <section id="CD015122-sec-0077"> <h5 class="title">Analyzes of primary outcomes</h5> <section id="CD015122-sec-0078"> <h6 class="title">Blood transfusion</h6> <p>Based on the pooled control baseline risk of blood transfusion in the control (non‐TXA) study population, systemic TXA probably reduces blood transfusions (risk ratio (RR) 0.45, 95% confidence interval (CI) 0.27 to 0.76; I<sup>2</sup> = 28%; 9 studies, 1353 participants; moderate‐certainty of evidence (CoE); <a href="./references#CD015122-fig-0003" title="">Analysis 1.1</a>). We assumed a minimally clinically important difference (MCID) of ≥ 2%. Based on 111 participants per 1000 with placebo (or no TXA) being transfused, this corresponds to 61 fewer (from 81 fewer to 27 fewer) transfused participants per 1000. </p> <p>We downgraded the certainty of evidence by one level (‐1) overall for concerns about study limitations, namely concerns over performance, detection and/or selective reporting bias. </p> <p>Due to concerns about the control baseline risk of blood transfusion in the control group (non‐TXA) study population being higher than that reflected by more recent literature, we selected a blood transfusion rate from a large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>) to serve as an adjusted control baseline risk (5.7%). Based on this adjusted baseline risk, systemic TXA may reduce blood transfusions (RR 0.45, 95% CI 0.27 to 0.76; I<sup>2</sup> = 28%; 9 studies, 1353 participants; low CoE). We assumed an MCID of ≥ 2%. Based on 57 participants per 1000 with placebo (or no TXA) being transfused, this corresponds to 31 fewer (from 42 fewer to 14 fewer) transfused participants per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐1) due to a wide confidence interval consistent with a decrease or no change. </p> </section> <section id="CD015122-sec-0079"> <h6 class="title">Stone‐free rate (SFR)</h6> <p>Based on the pooled control baseline stone‐free rate in the control (non‐TXA) study population, systemic TXA may increase stone‐free rates (RR 1.11, 95% CI 0.98 to 1.27; I<sup>2</sup> = 62%; 4 studies, 603 participants; low CoE; <a href="./references#CD015122-fig-0004" title="">Analysis 1.2</a>). We assumed an MCID of ≥ 5%. Based on 620 participants per 1000 being stone free with placebo (or no TXA), this corresponds to 68 more (from 12 fewer to 168 more) stone‐free participants per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as inconsistency (‐1) due to clinically relevant inconsistency and high I<sup>2</sup>. Although this study demonstrated imprecision due to a wide confidence interval consistent with an increase and no change, we only downgraded once because we had already downgraded for inconsistency. </p> <p>Due to concerns about the control baseline risk of blood transfusion in the control group (non‐TXA) study population being higher than that reflected by more recent literature, we selected a blood transfusion rate from a large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>) to serve as an adjusted control baseline risk as noted above. The corresponding stone‐free rate cited in this study was therefore used for an adjusted control baseline rate for this analysis (75.7%). Based this adjusted baseline rate, systemic TXA may increase stone‐free rates (RR 1.11, 95% CI 0.98 to 1.27; I<sup>2</sup> = 62%; 4 studies, 603 participants; low CoE). We assumed an MCID of ≥ 5%. Based on 757 participants per 1000 being stone free with placebo (or no TXA), this corresponds to 83 more (from 15 fewer to 204 more) stone‐free participants per 1000. </p> <p>Similar to the first analysis, we downgraded the certainty of evidence for this second analysis with control adjusted baseline risk by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as inconsistency (‐1) due to clinically‐relevant inconsistency and high I<sup>2</sup>. Once again, we only downgraded once despite the imprecision with a wide confidence interval because we already downgraded for inconsistency. </p> </section> <section id="CD015122-sec-0080"> <h6 class="title">Thromboembolic events (TEEs)</h6> <p>There is probably no difference in TEE (risk difference (RD) 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = 0%; 6 studies, 841 participants; moderate CoE; <a href="./references#CD015122-fig-0005" title="">Analysis 1.3</a>). We assumed an MCID of ≥ 2%. Since there were no TEEs in intervention and/or control groups in 5 out of 6 studies, we opted to assess a risk difference with systemic TXA for this outcome. </p> <p>We downgraded the certainty of evidence by one levels (‐1) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias. </p> </section> </section> <section id="CD015122-sec-0081"> <h5 class="title">Analyzes of secondary outcomes</h5> <section id="CD015122-sec-0082"> <h6 class="title">Adverse events (AEs)</h6> <p>Systemic TXA may increase AEs (RR 5.22, 95% CI 0.52 to 52.72; I<sup>2</sup> = 75%; 4 studies, 602 participants; low CoE; <a href="./references#CD015122-fig-0006" title="">Analysis 1.4</a>). We assumed an MCID of ≥ 5%. Based on 23 participants per 1000 with placebo (or no TXA) having an AE, this corresponds to 98 more (from 11 fewer to 1000 more) participants with AEs per 1000. The only adverse event AE encountered was nausea. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as inconsistency (‐1) due to clinically relevant inconsistency and high I<sup>2</sup>. Although this study demonstrated imprecision due to a wide confidence interval consistent with an increase and no change, we only downgraded once because we already downgraded for inconsistency. </p> </section> </section> <section id="CD015122-sec-0083"> <h5 class="title">Secondary interventions</h5> <p>Systemic TXA may have little to no effect on secondary interventions (RR 1.15, 95% CI 0.84 to 1.57; I<sup>2</sup> = 0%; 2 studies, 319 participants; low CoE; <a href="./references#CD015122-fig-0007" title="">Analysis 1.5</a>). We assumed an MCID of ≥ 5%. Based on 278 participants per 1000 with placebo (or no TXA) having a secondary intervention, this corresponds to 42 more (from 44 fewer to 158 more) participants with secondary intervention per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐1) due to a wide confidence consistent with an increase or no change. </p> <section id="CD015122-sec-0084"> <h6 class="title">Major surgical complications</h6> <p>Systemic TXA probably reduces major surgical complications (RR 0.36, 95% CI 0.21 to 0.62; I<sup>2</sup> = 0%; 5 studies, 733 participants; moderate CoE; <a href="./references#CD015122-fig-0008" title="">Analysis 1.6</a>). We assumed an MCID of ≥ 2%. Based on 130 participants per 1000 with placebo (or no TXA) having a major surgical complication, this corresponds to 83 fewer (from 103 fewer to 49 fewer) participants with a major surgical complication per 1000. </p> <p>We downgraded the certainty of evidence by one level (‐1) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias. </p> <p>Due to concerns about the control baseline risk of blood transfusion in the control group (non‐TXA) study population being higher than that reflected by more recent literature, we selected a blood transfusion rate from a large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>) to serve as an adjusted control baseline risk as noted above. The corresponding major surgical complication rate cited in this study was therefore used for an adjusted control baseline risk (4.1%). Based this adjusted baseline rate, systemic TXA may reduce major surgical complications (RR 0.36, 95% CI 0.21 to 0.62; I<sup>2</sup> = 0%; 5 studies, 733 participants; low CoE). We assumed an MCID of ≥ 2%. Based on 41 participants per 1000 with placebo (or no TXA) having a major surgical complication, this corresponds to 26 fewer (from 32 fewer to 16 fewer) participants with a major surgical complication per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐1) due to a wide confidence consistent with a decrease or no change. </p> </section> <section id="CD015122-sec-0085"> <h6 class="title">Minor surgical complications</h6> <p>Systemic TXA may reduce minor surgical complications (RR 0.71, 95% CI 0.45 to 1.10; I<sup>2</sup> = 76%; 5 studies, 733 participants; low CoE; <a href="./references#CD015122-fig-0009" title="">Analysis 1.7</a>). We assumed an MCID of ≥ 5%. Based on 396 participants per 1000 with placebo (or no TXA) having a minor surgical complication, this corresponds to 115 fewer (from 218 fewer to 40 more) participants with a minor surgical complication per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as inconsistency (‐1) due to clinically relevant inconsistency and high I<sub>2</sub>. Although this study demonstrated imprecision due to a wide confidence interval consistent with a decrease and no change, we only downgraded once because we already downgraded for inconsistency. </p> </section> <section id="CD015122-sec-0086"> <h6 class="title">Unplanned hospitalizations or readmissions</h6> <p>We are very uncertain how unplanned readmissions are affected (RR 1.55, 95% CI 0.45 to 5.31; I<sup>2</sup> = not applicable; 1 study, 189 participants; very low CoE; <a href="./references#CD015122-fig-0010" title="">Analysis 1.8</a>). We assumed an MCID of ≥ 2%. Based on 42 participants per 1000 with placebo (or no TXA) readmitted, this corresponds to 23 more (from 23 fewer to 180 more) participants readmitted per 1000. </p> <p>We downgraded the certainty of evidence by three levels (‐3) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐2) due to a very wide confidence interval consistent with both an increase, no change, or a decrease. </p> </section> <section id="CD015122-sec-0087"> <h6 class="title">Hospital length of stay</h6> <p>Systemic TXA may reduce hospital length of stay (mean difference 0.52 days lower, 95% CI 0.93 lower to 0.11 lower; I<sup>2</sup> = 98%; 7 studies, 1151 participants; low CoE; <a href="./references#CD015122-fig-0011" title="">Analysis 1.9</a>). We assumed an MCID of ≥ 0.5 days. </p> <p>The <a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a> study reported a median length of hospital stay with range. We were able to calculate mean hospital length stay and standard deviation (SD) by utilizing equations described by <a href="./references#CD015122-bbs2-0111" title="WanX , WangW , LiuJ , TongT . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology2014;14(1):135. [DOI: 10.1186/1471-2288-14-135]">Wan 2014</a> as recommended by the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD015122-bbs2-0053" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023.. Available from www.training.cochrane.org/handbook..">Higgins 2023_A</a>). We were unable to include data from <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a> since the SD was calculated to be 0 in both arms based on reported results (indicating that all patients were hospitalized for 4 days). In order to include this study we therefore imputed a SD of 0.01 in both arms. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as inconsistency (‐1) due to clinically relevant inconsistency and high I‐square. Although this study demonstrated imprecision due to a wide confidence interval consistent with a decrease and no change, we only downgraded once because we already downgraded for inconsistency. </p> </section> </section> </section> <section id="CD015122-sec-0088"> <h4 class="title">Subgroup analyzes</h4> <p>We were unable to conduct any of the predefined subgroup analyzes based on the number of access sites, targeted calyx, access sheath size or stone size due to lack of relevant data reported in the included studies. </p> </section> <section id="CD015122-sec-0089"> <h4 class="title">Sensitivity analyzes</h4> <section id="CD015122-sec-0090"> <h5 class="title">Sensitivity analysis of primary and secondary outcomes for risk of bias</h5> <p>A single study (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>) was used for the sensitivity analysis for risk of bias for primary outcomes as it was the only study rated to have low risk of bias for all domains. All other studies were excluded for this sensitivity analysis due to domain(s) rated as unclear or high risk of bias. </p> <section id="CD015122-sec-0091"> <h6 class="title">Blood transfusion</h6> <p>The RR in this subset of studies was 0.21 (95% CI: 0.05 to 0.92; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0012" title="">Analysis 1.10</a>). This result supports the findings of our primary analysis, but the effect size appears smaller. </p> </section> <section id="CD015122-sec-0092"> <h6 class="title"><i>S</i>tone‐free rate (SFR) </h6> <p>The RR in this subset of studies was 1.99 (95% CI: 1.12 to 3.55; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0013" title="">Analysis 1.11</a>). This result supports the findings of our primary analysis, but the effect size appears larger. </p> </section> <section id="CD015122-sec-0093"> <h6 class="title">Thromboembolic events (TEEs)</h6> <p>The RD in this subset of studies was 0.02 (95% CI: ‐0.01 to 0.06; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0014" title="">Analysis 1.12</a>). This result suggests an increased risk of TEE in patients who receive systemic TXA, but the confidence interval is wide. </p> </section> <section id="CD015122-sec-0094"> <h6 class="title">Adverse events (AEs)</h6> <p>This sensitivity analysis could not be performed as the <a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a> study did not report AEs as an outcome. </p> </section> </section> <section id="CD015122-sec-0095"> <h5 class="title">Secondary interventions</h5> <p>The RR in this subset of studies was 1.19 (95% CI: 0.86 to 1.64; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0015" title="">Analysis 1.13</a>). This result supports the findings of our primary analysis with similar effect size. </p> <section id="CD015122-sec-0096"> <h6 class="title">Major surgical complications</h6> <p>The RR in this subset of studies was 0.52 (95% CI: 0.13 to 2.00; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0016" title="">Analysis 1.14</a>). This result supports the findings of our primary analysis. The effect size appears larger, but the confidence interval is wider. </p> </section> <section id="CD015122-sec-0097"> <h6 class="title">Minor surgical complications</h6> <p>The RR in this subset of studies was 0.76 (95% CI: 0.37 to 1.56; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0017" title="">Analysis 1.15</a>). This result supports the findings of our primary analysis with similar effect size. </p> </section> <section id="CD015122-sec-0098"> <h6 class="title">Unplanned hospitalizations or readmissions</h6> <p>The RR in this subset of studies was 1.55 (95% CI: 0.45 to 5.31; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0018" title="">Analysis 1.16</a>). This is the same as our primary analysis since both included the same single study. </p> </section> <section id="CD015122-sec-0099"> <h6 class="title">Hospital length of stay</h6> <p>The mean difference in this subset of studies was 0.45 days lower (95% CI: 0.97 lower to 0.07 greater; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0019" title="">Analysis 1.17</a>). This result supports the findings of our primary analysis. The effect size is smaller, and the confidence interval includes an increase of 0.07 days for hospital length of stay; however, this increase remains below our MCID of ≥ 0.5 days. </p> </section> </section> </section> <section id="CD015122-sec-0100"> <h4 class="title">Sensitivity analysis of primary and secondary outcomes for definition of stone‐free rate (&lt; 2 mm residual stone fragment) </h4> <p>A total of four studies for systemic TXA reported stone‐free rates (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>). The <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a> study cited a complete stone‐free rate, so it was also included in this sensitivity analysis. Three studies defined stone clearance success as either complete stone clearance or the presence of residual fragments less than 4 mm (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>). However, the <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a> study only reported a complete stone clearance rate within its results; therefore, it was used for this sensitivity analysis. The <a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a> study reported both a complete stone clearance rate and a success rate for those with no residual fragments greater than 4 mm. The sensitivity analysis was therefore performed by substituting the complete stone clearance rate for the success rate (no residual fragments &gt; 4mm) as reported by the <a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a> study. The <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a> study reported a stone‐free rate but did not clarify if this referred to their definition of success or a complete stone clearance, so it was excluded for the sensitivity analysis. </p> <section id="CD015122-sec-0101"> <h5 class="title">Blood transfusion</h5> <p>The RR in this subset of studies was 0.20 (95% CI: 0.08 to 0.46; I<sup>2</sup> = 0%; 3 studies, 553 participants; <a href="./references#CD015122-fig-0020" title="">Analysis 1.18</a>). This result supports the findings of our primary analysis, but the effect size appears smaller. </p> </section> <section id="CD015122-sec-0102"> <h5 class="title">Stone‐free rate (SFR)</h5> <p>The RR in this subset of studies was 1.16 (95% CI: 0.95 to 1.42; I<sup>2</sup> = 61%; 3 studies, 553 participants; <a href="./references#CD015122-fig-0021" title="">Analysis 1.19</a>). This result supports the findings of our primary analysis with similar effect size. </p> </section> <section id="CD015122-sec-0103"> <h5 class="title">Thromboembolic events (TEEs)</h5> <p>The RD in this subset of studies was 0.00 (95% CI: ‐0.01 to 0.02; I<sup>2</sup> = 0%; 3 studies, 553 participants; <a href="./references#CD015122-fig-0022" title="">Analysis 1.20</a>). This result supports the findings of our primary analysis with similar effect size. </p> </section> <section id="CD015122-sec-0104"> <h5 class="title">Adverse events (AEs)</h5> <p>The RR in this subset of studies was 2.23 (95% CI: 0.06 to 85.18; I<sup>2</sup> = 66%; 2 studies, 364 participants; <a href="./references#CD015122-fig-0023" title="">Analysis 1.21</a>). This result supports the findings of our primary analysis. The effect size appears smaller, and there is a similarly wide confidence interval. </p> </section> <section id="CD015122-sec-0105"> <h5 class="title">Secondary interventions</h5> <p>The RR in this subset of studies was 1.19 (95% CI: 0.86 to 1.64; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0024" title="">Analysis 1.22</a>). This result supports the findings of our primary analysis with similar effect size. </p> <section id="CD015122-sec-0106"> <h6 class="title">Major surgical complications</h6> <p>The RR in this subset of studies was 0.34 (95% CI: 0.19 to 0.61; I<sup>2</sup> = 0%; 3 studies, 553 participants; <a href="./references#CD015122-fig-0025" title="">Analysis 1.23</a>). This result supports the findings of our primary analysis with similar effect size. </p> </section> <section id="CD015122-sec-0107"> <h6 class="title">Minor surgical complications</h6> <p>The RR in this subset of studies was 0.58 (95% CI: 0.42 to 0.78; I<sup>2</sup> = 0%; 3 studies, 553 participants; <a href="./references#CD015122-fig-0026" title="">Analysis 1.24</a>). This result supports the findings of our primary analysis. The effect size appears smaller, and the confidence interval is more narrow. </p> </section> <section id="CD015122-sec-0108"> <h6 class="title">Unplanned hospitalizations or readmissions</h6> <p>The RR in this subset of studies was 1.55 (95% CI: 0.45 to 5.31; I<sup>2</sup> = not applicable; 1 study, 189 participants; <a href="./references#CD015122-fig-0027" title="">Analysis 1.25</a>). This is the same as our primary analysis since both included the same single study. </p> </section> <section id="CD015122-sec-0109"> <h6 class="title">Hospital length of stay</h6> <p>The mean difference (MD) in this subset of studies was 1.07 days lower (95% CI 1.68 lower to 0.45 lower; I<sup>2</sup> = 84%; 3 studies, 553 participants; <a href="./references#CD015122-fig-0028" title="">Analysis 1.26</a>). This result supports the findings of our primary analysis, but the effect size appears larger. </p> </section> </section> </section> <section id="CD015122-sec-0110"> <h4 class="title">Topical TXA compared to no TXA (placebo or usual care)</h4> <section id="CD015122-sec-0111"> <h5 class="title">Analyzes of Primary Outcomes for Topical TXA</h5> <section id="CD015122-sec-0112"> <h6 class="title">Blood transfusion</h6> <p>Topical TXA probably reduces blood transfusions (RR 0.40, 95% CI 0.20 to 0.81; I<sup>2</sup> = not applicable; 1 study, 400 participants; moderate CoE; <a href="./references#CD015122-fig-0029" title="">Analysis 2.1</a>). We assumed an MCID of ≥ 2%. Based on 125 participants per 1000 with placebo (or no TXA) being transfused, this corresponds to 75 fewer (from 100 fewer to 24 fewer) transfused participants per 1000. </p> <p>We downgraded the certainty of evidence by one level (‐1) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias. </p> <p>Due to concerns about the control baseline risk of blood transfusion in the control group (non‐TXA) study population being higher than that reflected by more recent literature, we selected a blood transfusion rate from a large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>) to serve as an adjusted control baseline risk (5.7%). Based this adjusted baseline risk, topical TXA may reduce blood transfusions (RR 0.40, 95% CI 0.20 to 0.81; I<sup>2</sup> = not applicable; 1 study, 400 participants; low CoE). We assumed an MCID of ≥ 2%. Based on 57 participants per 1000 with placebo (or no TXA) being transfused, this corresponds to 34 fewer (from 46 fewer to 11 fewer) transfused participants per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐1) due to a wide confidence consistent with a decrease or no change. </p> </section> <section id="CD015122-sec-0113"> <h6 class="title"><i>S</i>tone‐free rate (SFR) </h6> <p>Topical TXA may improve stone‐free rate. (RR 1.07, 95% CI 0.99 to 1.17; I<sup>2</sup> = not applicable; 1 study, 400 participants; low CoE; <a href="./references#CD015122-fig-0030" title="">Analysis 2.2</a>). We assumed an MCID of ≥ 5%. Based on 820 participants per 1000 being stone free with placebo (or no TXA), this corresponds to 57 more (from 8 fewer to 139 more) stone‐free participants per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐1) due to a wide confidence interval consistent with an increase or no change. </p> <p>Due to concerns about the control baseline risk of blood transfusion in the control group (non‐TXA) study population being higher than that reflected by more recent literature, we selected a blood transfusion rate from a large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>) to serve as an adjusted control baseline risk as noted above. The corresponding stone‐free rate cited in this study was therefore used for an adjusted control baseline rate (75.7%). Based this adjusted baseline rate, topical TXA may improve stone‐free rate. (RR 1.07, 95% CI 0.99 to 1.17; I<sup>2</sup> = not applicable; 1 study, 400 participants; low COE). We assumed an MCID of ≥ 5%. Based on 757 participants per 1000 being stone free with placebo (or no TXA), this corresponds to 53 more (from 8 fewer to 129 more) stone‐free participants per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐1) due to a wide confidence consistent with an increase or no change. </p> </section> <section id="CD015122-sec-0114"> <h6 class="title">Thromboembolic events (TEEs)</h6> <p>There is probably no difference in TEE (RD 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = not applicable; 1 study, 400 participants; moderate CoE; <a href="./references#CD015122-fig-0031" title="">Analysis 2.3</a>). We assumed an MCID of ≥ 2%. Since there were no thromboembolic events in the intervention nor the control groups, we opted to assess a risk difference with topical TXA for this outcome. </p> <p>We downgraded the certainty of evidence by one levels (‐1) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias. </p> </section> </section> </section> <section id="CD015122-sec-0115"> <h4 class="title">Analyses of Secondary Outcomes for Topical TXA</h4> <section id="CD015122-sec-0116"> <h5 class="title">Adverse events (AES)</h5> <p>There is probably no difference in AES (RD 0.00, 95% CI ‐0.01 to 0.01; I<sup>2</sup> = not applicable; 1 study, 400 participants; moderate CoE; <a href="./references#CD015122-fig-0032" title="">Analysis 2.4</a>). We assumed an MCID of ≥ 5%. Since there were no adverse events in the intervention nor the control groups, we opted to assess a risk difference with topical TXA for this outcome. </p> <p>We downgraded the certainty of evidence by one levels (‐1) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias. </p> </section> <section id="CD015122-sec-0117"> <h5 class="title">Secondary interventions</h5> <p>We found no evidence for this outcome.</p> <section id="CD015122-sec-0118"> <h6 class="title">Major surgical complications</h6> <p>Topical TXA may reduce major surgical complications (RR 0.69, 95% CI 0.45 to 1.06; I<sup>2</sup> = not applicable; 1 study, 400 participants; low CoE; <a href="./references#CD015122-fig-0033" title="">Analysis 2.5</a>). We assumed an MCID of ≥ 2%. Based on 210 participants per 1000 with placebo (or no TXA) having a major surgical complication, this corresponds to 65 fewer (from 116 fewer to 13 more) participants with a major surgical complication per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐1) due to a wide confidence interval consistent with both a decrease or no change. </p> <p>Due to concerns about the control baseline risk of blood transfusion in the control group (non‐TXA) study population being higher than that reflected by more recent literature, we selected a blood transfusion rate from a large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>) to serve as an adjusted control baseline risk as noted above. The corresponding major complication rate cited in this study was therefore used for an adjusted control baseline risk (4.1%). Based this adjusted baseline risk, topical TXA may reduce major surgical complications. (RR 0.69, 95% CI 0.45 to 1.06; I<sup>2</sup> = not applicable; 1 study, 400 participants; low COE). We assumed an MCID of ≥ 2%. Based on 41 participants per 1000 being stone free with placebo (or no TXA), this corresponds to 13 fewer (from 23 fewer to 2 more) stone‐free participants per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐1) due to a wide confidence interval consistent with both a decrease or no change. </p> </section> <section id="CD015122-sec-0119"> <h6 class="title">Minor surgical complications</h6> <p>Topical TXA may reduce minor surgical complications (RR 0.73, 95% CI 0.59 to 0.91; I<sup>2</sup> = not applicable; 1 study, 400 participants; low CoE; <a href="./references#CD015122-fig-0034" title="">Analysis 2.6</a>). We assumed an MCID of ≥ 5%. Based on 520 participants per 1000 with placebo (or no TXA) having a minor surgical complication, this corresponds to 140 fewer (from 213 fewer to 47 fewer) participants with a minor surgical complication per 1000. </p> <p>We downgraded the certainty of evidence by two levels (‐2) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias, as well as imprecision (‐1) due to a wide confidence interval consistent with both a decrease or no change. </p> </section> <section id="CD015122-sec-0120"> <h6 class="title">Unplanned hospitalizations or readmissions</h6> <p>We found no evidence for this outcome.</p> </section> <section id="CD015122-sec-0121"> <h6 class="title">Hospital length of stay</h6> <p>Topical TXA probably reduces hospital length of stay (mean difference (MD) 1.26 lower, 95% CI 1.49 lower to 1.03 lower; I<sup>2</sup> = not applicable; 1 study, 400 participants; moderate CoE; <a href="./references#CD015122-fig-0035" title="">Analysis 2.7</a>). We assumed an MCID of ≥ 0.5 days. </p> <p>We downgraded the certainty of evidence by one level (‐1) overall for concerns about study limitations (‐1), namely concerns over performance, detection and/or selective reporting bias. </p> </section> </section> </section> <section id="CD015122-sec-0122"> <h4 class="title">Subgroup analyzes</h4> <p>We were unable to conduct any of the predefined subgroup analyzes based on number of access sites, targeted calyx, access sheath size or stone size due to lack of relevant data reported in the included study. </p> </section> <section id="CD015122-sec-0123"> <h4 class="title">Sensitivity analyzes</h4> <section id="CD015122-sec-0124"> <h5 class="title">Sensitivity analysis of primary and secondary outcomes for risk of bias</h5> <p>We were unable to perform this sensitivity analysis for any of the primary or secondary outcomes as the single included study (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>) had several ratings of unclear risk of bias. </p> </section> <section id="CD015122-sec-0125"> <h5 class="title">Sensitivity analysis of primary and secondary outcomes for definition of stone‐free rate (&lt; 2 mm residual stone fragment) </h5> <p>The single included study for topical TXA (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>) defined stone clearance success as quote:"either complete stone clearance or the presence of residual fragments less than 4 mm;" however, within the results of this study only a rate for complete stone clearance was reported. Since no rate for the success as defined as fragments less than 4 mm was reported, we were unable to perform this sensitivity analysis for any of the primary or secondary outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015122-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015122-sec-0126"></div> <section id="CD015122-sec-0127"> <h3 class="title" id="CD015122-sec-0127">Summary of main results</h3> <p>Based on a body of evidence that included 10 randomzsed controlled trial (RCTs), we found that systemic administration of tranexamic acid (TX)A compared to placebo and usual case (or usual care alone) may reduce the risk of blood transfusion in average risk patients undergoing percutaneous nephrolithotomy (PCNL) and may also increase stone‐free rates. It probably has no effect on the risk of thromboembolic events. When it comes to secondary outcomes, overall adverse events (in the form of nausea) may be increased, whereas major surgical, minor complications and length of stay may be reduced. There may be little to no effect on secondary interventions. We are uncertain how systemic TXA compared to placebo and usual case or usual care alone effects unplanned hospital admissions/readmissions. </p> <p>Based on a single trial, we found that topical administration of TXA compared to placebo and usual case or usual care alone, may also reduce the risk of blood transfusions in average risk patients and may improve stone‐free rates. It probably has no effect on risk of thromboembolic events. When it comes to secondary outcomes, both major and minor surgical complications may be reduced and hospital length of stay is probably reduced. Topical TXA probably has no effect on the risk of adverse events. We found no evidence for the outcomes of secondary interventions and unplanned hospital admissions/readmissions. </p> </section> <section id="CD015122-sec-0128"> <h3 class="title" id="CD015122-sec-0128">Overall completeness and applicability of evidence</h3> <p>The majority of studies identified in this review addressed the systemic use of TXA. These studies were mainly conducted in middle‐ to low‐income countries in populations of individuals that were younger and may have been healthier than those treated in higher‐income countries. Stone burden and type and location of PCNL access appear representative of how PCNLs are performed in most countries though. Based on the published literature, we found the risk of blood transfusion and major surgical complications rates in the non‐TXA groups to be high, whereas the stone‐free rates were relatively low. To address generalizability, we therefore derived more representative baseline risks for these outcomes for these outcomes based on a large international observational study (<a href="./references#CD015122-bbs2-0036" title="dela RosetteJJ , OpondoD , DaelsFP , GiustiG , SerranoA , KandasamiSV , et al, CROES PCNL Study Group. Categorisation of complications and validation of the Clavien score for percutaneous nephrolithotomy. European Urology2012;62(2):246-55. [PMID: 22487016]">de la Rosette 2012</a>). Doing so, generated different absolute effect sizes estimates, but left the conclusions of this review largely unchanged. The same applies to the result of a single (yet relatively large) RCT on the use of topical TXA from India (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>). </p> <p>It also appears important to highlight that based on the available body of evidence summarized in this review, we remain very uncertain about the risk of thromboembolic events. While these are likely rare (here: two events among 418 participants [0.5%] receiving systemic TXA) they represent a potentially critical harm that should inform the decision to use TXA or not. Indirect evidence from other settings of TXA use, both from RCTs and non‐RCTS may be necessary to better inform that risk. </p> </section> <section id="CD015122-sec-0129"> <h3 class="title" id="CD015122-sec-0129">Quality of the evidence</h3> <p>The certainty of evidence on a per‐outcome basis ranged from moderate to very low in this review. Reasons for rating down were as follows. </p> <p> <ul id="CD015122-list-0026"> <li> <p>Study limitations: we consistently rated down the certainty of evidence of all outcomes due to concerns about risk of bias. For most studies, the risk of bias for allocation concealment (selection bias) and blinding of participants and personnel (performance bias) was unclear. In addition, only a single trial (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>) was able to account for a registered protocol, thereby raising concerns over selective reporting bias. We also included one trial (<a href="./references#CD015122-bbs2-0005" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 2</a>; <a href="./references#CD015122-bbs2-0006" title="MaghsoudiR , EtemadianM , AmeliM , MeshkiI . Evaluation of the efficacy of tranexamic acid injection on surgical bleeding in percutaneous nephrolithotomy: a randomized clinical trial. Journal of Endourology2018;32:A266-7. [DOI: 10.1089/end.2018.29043.abstracts]">Maghsoudi 2018_Group 3</a>) which was only available in abstract form, thereby leaving much of its methodology unclear. </p> </li> <li> <p>Inconsistency: for several outcomes (stone‐free rates, minor surgical complications, hospital length of stay) in the comparison of systemic TXA and usual care to placebo and usual care alone, or both were found clinically relevant, yet ultimately unexplained heterogeneity that lowered our confidence in the pooled effect size. The different dosing regimens used by the included trials may be a potential source of heterogeneity </p> </li> <li> <p>Imprecision: given relative low numbers of participants or event rates, we rated down further if the confidence intervals crossed predefined threshold for minimally clinically importance differences. (MCIDs) </p> </li> <li> <p>Completeness of follow‐up: although most outcomes of this review were short term, and rates of attrition were low, it should be noted that several studies did not report the length of follow‐up. </p> </li> </ul> </p> </section> <section id="CD015122-sec-0130"> <h3 class="title" id="CD015122-sec-0130">Potential biases in the review process</h3> <p>All aspects of this review followed Cochrane guidance and were based on a peer‐reviewed and published protocol (<a href="./references#CD015122-bbs2-0117" title="ClevelandB , NorlingB , WangH , GandhiV , PriceCL , BorofskyM , et al. Tranexamic acid for percutaneous nephrolithotomy. Cochrane Database of Systematic Reviews2022, Issue 3. Art. No: CD015122. [DOI: 10.1002/14651858.CD015122]">Cleveland 2022</a>). The most relevant source of bias to the review relates to the comprehensiveness of the search. Although we sought to conduct an exhaustive search for published and unpublished studies irrespective of language, it is possible that further trials, in particular those with "negative" results, exist but escaped our attention. Especially studies from non‐English studies are at risk for being missed in reviews such as these and our ability to conduct formal statistical tests for publication bias was limited to the low number of studies informing most outcomes. </p> </section> <section id="CD015122-sec-0131"> <h3 class="title" id="CD015122-sec-0131">Agreements and disagreements with other studies or reviews</h3> <p>Several systematic reviews have focused on the use of tranexamic acid (TXA) in the percutaneous nephrolithotomy (PCNL)setting, but most have serious methodological limitations and none to date has rated the certainty of evidence on a per‐outcome basis. </p> <p> <ul id="CD015122-list-0027"> <li> <p><a href="./references#CD015122-bbs2-0042" title="FengD , ZhangF , LiuS , HanP , WeiW . Efficacy and safety of the tranexamic acid in reducing blood loss and transfusion requirements during percutaneous nephrolithotomy: a systematic review and meta-analysis of randomized controlled trials. Minerva Urology and Nephrology2020;72(5):579-85.">Feng 2020</a> is a systematic review with the latest search date of March 2020. It included three RCTs (<a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) which are also included in our review. It differs from our review as not having a registered protocol and not providing a certainty of evidence rating. It is notable that the included studies risk of bias assessments were considerably more favorable than ours. For example, we found the risk of allocation concealment for two studies (<a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) to be unclear, whereas the authors report it to have been low risk. The authors concluded the use of TXA to be promising, but further well‐designed trials being warranted. </p> </li> <li> <p><a href="./references#CD015122-bbs2-0112" title="WangZ , HeX , BaiY , WangJ . Can tranexamic acid reduce the blood transfusion rate in patients undergoing percutaneous nephrolithotomy? A systematic review and meta-analysis. Journal of International Medical Research2020;48(4):300060520917563.">Wang 2020</a> is a systematic review with the latest search date of October 2019. It used the outdated Jadad system for assessing study quality and did not rate the certainty of evidence using GRADE. It reported the inclusion of six RCTs. Of these, four (<a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) are also included in our review. One of the included studies (<a href="./references#CD015122-bbs2-0032" title="CauniV , MihaiV , BarbilianCR , DragutescuMD , BuragaI . The use of tranexamic acid for preventing hemorrhagic complications during percutaneous nephrolithotomy. European Urology, Supplements2017;16(11):e2972.">Cauni 2017</a>) the authors (falsely) included was a comparative observational study, not an RCTsas we confirmed through communication with the study authors. Another included study labeled as "Carlos 2019" did not include a reference but appears to have an abstract presentation of the study we included as full‐text (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>). </p> </li> <li> <p><a href="./references#CD015122-bbs2-0060" title="KallidonisP , VagionisA , PagonisK , PeteinarisA , PietropaoloA , AdamouC , et al. Is there any clinical benefit for peri-operative administration of tranexamic acid for patients undergoing percutaneous nephrolithotomy? A systematic review and meta-analysis. Current Urology Reports2021;22(12):65.">Kallidonis 2021</a> represents a systematic review with the latest search date of March 2020. It stands out for having a registered protocol in PROSPERO (CRD42019122818). It included a total of six RCTs (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>), which we also include here. Ultimately its authors excluded <a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a> given its distinct, topical route of administration of TXA. The study reported reduced odds of transfusion with the use of TXA; odds ratio(OR) 0.34 (95% CI: 0.19 to 0.64) and no statistical difference in stone‐free rates. The outcome of thromboembolic events was not assessed, and the review did not provide certainty of evidence ratings. </p> </li> <li> <p><a href="./references#CD015122-bbs2-0072" title="LeeMJ , KimJK , TangJ , MingJM , ChuaME . The efficacy and safety of tranexamic acid in the management of perioperative bleeding after percutaneous nephrolithotomy: a systematic review and meta-analysis of comparative studies. Journal of Endourology2022;36(3):303-12.">Lee 2022</a> searched the literature up to March 2021 and included eight trials (<a href="./references#CD015122-bbs2-0001" title="BansalA , AroraA . A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World journal of Urology2017;35(8):1233-40. [DOI: 10.1007/s00345-016-1980-6]">Bansal 2017</a>; <a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>) as well as three comparative observational studies. A protocol for this systematic review was registered (CRD42021240308). Appropriately, randomized and non‐randomized trials were pooled separately. Thromboembolic events were not considered as an outcome and the certainty of evidence was not assessed. The authors reported a number needed to treat of 11 to prevent one transfusion and stated that "TXA can effectively reduce postoperative bleeding after PCNL". </p> </li> <li> <p><a href="./references#CD015122-bbs2-0074" title="MacDonaldM , IlieG , PowerL , WhalenS , ParkerR , SkinnerTA , et al. Effect of tranexamic acid on bleeding outcomes after percutaneous nephrolithotomy: a systematic review and meta-analysis of randomized controlled trials. Journal of Endourology2022;36(5):589-97.">MacDonald 2022</a> searched the literature up to July 2021 and included 7 trials (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) with a Jadad score of three or greater. Once again, thromboembolic events as a main potential treatment‐related harm were not considered as an outcome and the certainty of evidence was not assessed. The authors concluded that "routine use of TXA at time of PCNL reduces the rates of blood transfusion....and operative time" and that "stronger consideration should be given to the routine use of TXA during PCNL by endoscopic surgeons". </p> </li> <li> <p><a href="./references#CD015122-bbs2-0025" title="BaccagliniW , RodriguesAF , GlinaFP , DallAquaV , GlinaS , NetoAC . Tranexamic acid use for hemorrhagic events prevention in percutaneous nephrolithotomy: systematic review and meta-analysis. Journal of Endourology2022;36(7):906-15.">Baccaglini 2022</a> searched the literature up to August 2021 and had a registered protocol (CRD42020182197). It included 7 RCTs (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) which are all represented in our review. Limitations of this review are similar to those described above; most importantly the authors did not rate the certainty of evidence. The authors concluded that "the benefit of TXA use in the setting of PCNL perioperative is clear". </p> </li> <li> <p><a href="./references#CD015122-bbs2-0056" title="Hinojosa-GonzalezDE , Flores-VillalbaE , EisnerBH , Olvera-PosadaD . Tranexamic acid vs placebo and its impact on bleeding, transfusions and stone-free rates in percutaneous nephrolithotomy: a systematic review and meta-analysis. Central European Journal of Urology2022;75(1):81-9.">Hinojosa‐Gonzalez 2022</a> also had a registered protocol (CRD42021270593). Its latest search date was August 2021 and the authors included 8 RCTs (<a href="./references#CD015122-bbs2-0002" title="BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , DanilovicA, et al. Impact of intraoperative use of tranexamic acid on transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy: randomized, double-blind, placebo controlled trial. Journal of Urology2019;201(4):e1095-6. [DOI: 10.1097/01.JU.0000557193.21809.63]BatagelloCA , VicentiniFC , MongaM , MarchiniGS , TorricelliFC , M, DanilovicA , et al. Impact of intraoperative use of tranexamic acid in patients with complex kidney stones undergoing percutaneous nephrolithotomy: prospective, randomized, double-blind, placebo controlled trial. Journal of Urology2020;203:e61. [DOI: 10.1097/JU.0000000000000821.04]BatagelloCA , Vicentini C , MongaM , MillerAW , MarchiniGS , TorricelliF , et al. Tranexamic acid in patients with complex stones undergoing percutaneous nephrolithotomy: a randomized, double-blinded, placebo-controlled trial. BJU international2021;129(1):35-47. [DOI: 10.1111/bju.15378]NCT02966236. Impact of tranexamic acid use in percutaneous nephrolithotomy. https://clinicaltrials.gov/show/NCT029662362016;N/A:N/A. ">Batagello 2021</a>; <a href="./references#CD015122-bbs2-0003" title="IskakovY , MuratovT , PakY , SuchshenkoA , Zhaparov U, KhairlyG . Percutaneous nephroscopic surgery: using tranexamic acid to prevent intraoperative bleeding. Research Journal of Pharmaceutical Biological and Chemical Sciences2016;7(5):1782-93. [CORPUS ID: 26146663] [ISSN: 0975-8585]">Iskakov 2016</a>; <a href="./references#CD015122-bbs2-0004" title="KumarS , RandhawaMS , GanesamoniR , Singh K . Tranexamic acid reduces blood loss during percutaneous nephrolithotomy: a prospective randomized controlled study. Journal of Urology2013;189(5):1757-61. [DOI: 10.1016/j.juro.2012.10.115]">Kumar 2013</a>; <a href="./references#CD015122-bbs2-0007" title="IRCT20180209038673N. Effect of tranexamic acid in treatment of surgical bleeding. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20180209038673N12018;N/A:N/A. [DOI]MohammadiM , Nouri-MahdaviK , BarzegarA . Effects of tranexamic acid on bleeding and hemoglobin levels in patients with staghorn calculi undergoing percutaneous nephrolithotomy:randomized controlled trial. Iranian Journal of Medical Sciences2019;44(6):457-64. [DOI: 10.30476/ijms.2019.44969]">Mohammadi 2019</a>; <a href="./references#CD015122-bbs2-0008" title="IRCT20150420021869N. Tranexamic acid in percutaneous nephrolithotomy. http://www.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20150420021869N12018;N/A:N/A. [DOI]Mohammadi SichaniM , KazemiR , Nouri-MahdaviK, GholipourF. Re-evaluation of the efficacy of tranexamic acid in reducing blood loss in percutaneous nephrolithotomy:aA randomized clinical trial. Minerva Urologica e Nefrologica2019;71(1):55-62. [DOI: 10.23736/S0393-2249.18.03151-X]">Mohammadi Sichani 2019</a>; <a href="./references#CD015122-bbs2-0009" title="MokhtariMR , FarshidS , ModresiP , AbediF . The effects of tranexamic acid on bleeding control during and after Percutaneous Nephrolithotomy (PCNL): a randomized clinical trial. Journal of Urology2021;18(6):608-11. [DOI: 10.22037/uj.v18i.6505] [PMID: 34291443]">Mokhtari 2021</a>; <a href="./references#CD015122-bbs2-0010" title="RashidAO , AhmedHK , AliDM . The use of tranexamic acid in percutaneous nephrolithotomy. A randomized controlled study (Local Experience). Open Journal of Urology Dec 14, 2018;8(12):317-26. [DOI: 10.4236/oju.2018.812035]">Rashid 2018</a>; <a href="./references#CD015122-bbs2-0011" title="SiddiqA , KhalidS , MithaniH , AnisS , SharifI , Shaikh, J. Preventing excessive blood loss during percutaneous nephrolithotomy by using tranexamic acid: a double blinded prospective randomized controlled trial. Journal of Urological Surgery2017;4(4):195‐201. [DOI: 10.4274/jus.1589]">Siddiq 2017</a>) of systemic TXA use, which are all included in our review. Limitations of this review once again include a lack of any formal approach to evaluate the confidence we can place in the review findings. The authors found stalactitically improved transfusion and complication rates as well as improved stone‐free rates. </p> </li> <li> <p><a href="./references#CD015122-bbs2-0065" title="KimJ , AlrumaihA , DonnellyC , UyM , HoogenesJ , MatsumotoED . The impact of tranexamic acid on perioperative outcomes in urological surgeries: A systematic review and meta-analysis. Canadian Urological Association Journal2023;17(6):205-16.">Kim 2023</a> represents a recent systematic review with a registered protocol and a search date of January 2021. The study looked across urological indications and included 12 studies on PCNL, including seven RCTs (also included in our Cochrane Review). Pooling across RCT and non‐RCTs, the authors found a decreased blood loss (MD of 93 cc less; 95% CI: 158 cc less to 29 cc less) as well as a reduced risk of transfusion (RR 0.46; 95% CI: 0.36 to 0.59). They did not rate the certainty of evidence. </p> </li> <li> <p><a href="./references#CD015122-bbs2-0089" title="PrasadS , SharmaG , DevanaSK , KumarS , SharmaS . Is tranexamic acid associated with decreased need for blood transfusion in percutaneous nephrolithotomy: a systematic review and meta-analysis. Annals of the Royal College of Surgery of England2023;105(2):99-106.">Prasad 2023</a> published a systematic review with a registered protocol and a search date of March 2021. They included six published RCTs (also included in our Cochrane Review). They found reduced odds of transfusion (OR: 0.33; 95%CI: 0.21 to 0.52) as well as a reduced length of stay. Stone‐free rates were higher in the TXA group and no thromboembolic events were noted. The authors did not rate the certainty of evidence. </p> </li> </ul> </p> <p>Since thromboembolic events (TEEs) are rare events, any potential risk increase through the use of TXA may need to be explored through indirect evidence (beyond the indication of PCNL) in studies with longer follow‐up. Two recent systematic reviews (<a href="./references#CD015122-bbs2-0081" title="MuraoS , NakataH , RobertsI , YamakawaK . Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. Critical Care2021;25(1):380.">Murao 2021</a>; <a href="./references#CD015122-bbs2-0105" title="TaeuberI , WeibelS , HerrmannE , NeefV , SchlesingerT , KrankeP , et al. Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta-analysis, and meta-regression. JAMA Surgery2021;156(6):e210884.">Taeuber 2021</a>) have suggested that risk may not be increased. <a href="./references#CD015122-bbs2-0105" title="TaeuberI , WeibelS , HerrmannE , NeefV , SchlesingerT , KrankeP , et al. Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta-analysis, and meta-regression. JAMA Surgery2021;156(6):e210884.">Taeuber 2021</a> analyzed a total of 216 eligible trials including 125,550 patients. Total TEEs were found in 1020 (2.1%) in the group receiving TXA and 900 (2.0%) in the control group. The review found no association between TXA and risk for total TEEs (risk difference = 0.001; 95% CI, ‐0.001 to 0.002; P = .49) for venous thrombosis, pulmonary embolism, venous TEEs, myocardial infarction or ischemia, and cerebral infarction or ischemia. Similarly, <a href="./references#CD015122-bbs2-0081" title="MuraoS , NakataH , RobertsI , YamakawaK . Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. Critical Care2021;25(1):380.">Murao 2021</a> analyzed a total of 234 studies with 102,681 patients. They found was no evidence that TXA increased the risk of thrombotic events (RR = 1.00 [95% CI 0.93‐1.08]), seizures (1.18 [0.91‐1.53]), venous thromboembolism (1.04 [0.92‐1.17]), acute coronary syndrome (0.88 [0.78‐1.00]) or stroke (1.12 [0.98‐1.27]). They did suggest (based on a dose‐by‐dose sensitivity analysis) that seizures may be increased in patients receiving more than 2 g/day of TXA (3.05 [1.01‐9.20]). </p> <p>While these findings are reassuring, there has also been a recent high‐quality and protocol‐driven trial in patients with upper gastrointestinal bleeding, the so‐called HALT‐IT trial (<a href="./references#CD015122-bbs2-0050" title="Collaborators Halt-It Trial. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet2020;395(10241):1927-36.">HALT IT Collaborators 2020</a>), that randomly allocated 12,009 patients to receive TXA or matching placebo. It found that TXA did not reduce death from gastrointestinal bleeding but also that venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were more frequent in TXA group than in the placebo group (RR 1.85; 95% CI 1.15 to 2.98) with absolute rates of 0.8% and 0.4%, respectively. These findings suggest that an increased risk of thromboembolic events may be small, but real. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015122-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) flow diagram." data-id="CD015122-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD015122-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 1: Blood transfusion" data-id="CD015122-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 1: Blood transfusion</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 2: Stone‐free rate" data-id="CD015122-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 2: Stone‐free rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 3: Thromboembolic events" data-id="CD015122-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 3: Thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 4: Adverse events" data-id="CD015122-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 4: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 5: Secondary interventions" data-id="CD015122-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 5: Secondary interventions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 6: Major Surgical complications" data-id="CD015122-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 6: Major Surgical complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 7: Minor surgical complications" data-id="CD015122-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 7: Minor surgical complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 8: Unplanned hospitalizations or readmissions" data-id="CD015122-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 8: Unplanned hospitalizations or readmissions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 9: Hospital length of stay (days)" data-id="CD015122-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 9: Hospital length of stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 10: Blood transfusion (Sensitivity analysis &amp; Risk of bias)" data-id="CD015122-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 10: Blood transfusion (Sensitivity analysis &amp; Risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 11: Stone‐free rate (Sensitivity analysis &amp; Risk of bias)" data-id="CD015122-fig-0013" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 11: Stone‐free rate (Sensitivity analysis &amp; Risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 12: Thromboembolic events (Sensitivity analysis &amp; Risk of bias)" data-id="CD015122-fig-0014" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 12: Thromboembolic events (Sensitivity analysis &amp; Risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 13: Secondary interventions (Sensitivity analysis &amp; Risk of bias)" data-id="CD015122-fig-0015" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 13: Secondary interventions (Sensitivity analysis &amp; Risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 14: Major surgical Complications (Sensitivity analysis &amp; Risk of bias)" data-id="CD015122-fig-0016" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 14: Major surgical Complications (Sensitivity analysis &amp; Risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 15: Minor Surgical complications (Sensitivity analysis &amp; Risk of bias)" data-id="CD015122-fig-0017" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 15: Minor Surgical complications (Sensitivity analysis &amp; Risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 16: Unplanned hospitalizations or readmissions (Sensitivity analysis &amp; Risk of bias)" data-id="CD015122-fig-0018" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 16: Unplanned hospitalizations or readmissions (Sensitivity analysis &amp; Risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 17: Hospital length ofsStay (days) (Sensitivity analysis &amp; Risk of bias)" data-id="CD015122-fig-0019" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 17: Hospital length ofsStay (days) (Sensitivity analysis &amp; Risk of bias) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 18: Blood transfusion (Sensitivity analysis &amp; definition of stone freedom)" data-id="CD015122-fig-0020" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 18: Blood transfusion (Sensitivity analysis &amp; definition of stone freedom) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 19: Stone‐free rate (Sensitivity analysis &amp; definition of stone freedom)" data-id="CD015122-fig-0021" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 19: Stone‐free rate (Sensitivity analysis &amp; definition of stone freedom) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 20: Thromboembolic events (Sensitivity analysis &amp; definition of stone freedom)" data-id="CD015122-fig-0022" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 20: Thromboembolic events (Sensitivity analysis &amp; definition of stone freedom) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 21: Adverse Eeents (Sensitivity analysis &amp; definition of stone freedom)" data-id="CD015122-fig-0023" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 21: Adverse Eeents (Sensitivity analysis &amp; definition of stone freedom) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 22: Secondary interventions (Sensitivity analysis &amp; definition of stone freedom)" data-id="CD015122-fig-0024" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 22: Secondary interventions (Sensitivity analysis &amp; definition of stone freedom) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 23: Major surgical complications (Sensitivity analysis &amp; definition of stone freedom)" data-id="CD015122-fig-0025" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 23: Major surgical complications (Sensitivity analysis &amp; definition of stone freedom) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 24: Minor surgical complications (Sensitivity analysis &amp; definition of stone freedom)" data-id="CD015122-fig-0026" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 24: Minor surgical complications (Sensitivity analysis &amp; definition of stone freedom) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 25: Unplanned hospitalizations or readmissions (Sensitivity analysis &amp; definition of stone freedom)" data-id="CD015122-fig-0027" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 25: Unplanned hospitalizations or readmissions (Sensitivity analysis &amp; definition of stone freedom) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 26: Hospital length of stay (days) (Sensitivity analysis &amp; definition of Stone freedom)" data-id="CD015122-fig-0028" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Systemic TXA vs No TXA (placebo or usual care), Outcome 26: Hospital length of stay (days) (Sensitivity analysis &amp; definition of Stone freedom) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 1: Blood transfusion" data-id="CD015122-fig-0029" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 1: Blood transfusion</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 2: Stone‐free rate" data-id="CD015122-fig-0030" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 2: Stone‐free rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 3: Thromboembolic events" data-id="CD015122-fig-0031" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 3: Thromboembolic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 4: Adverse event" data-id="CD015122-fig-0032" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 4: Adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 5: Major surgical complications" data-id="CD015122-fig-0033" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 5: Major surgical complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 6: Minor surgical complications" data-id="CD015122-fig-0034" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 6: Minor surgical complications </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015122-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/urn:x-wiley:14651858:media:CD015122:CD015122-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 7: Hospital length of stay (days)" data-id="CD015122-fig-0035" src="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_t/tCD015122-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Topical TXA vs No TXA (placebo or usual care), Outcome 7: Hospital length of stay (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/media/CDSR/CD015122/image_n/nCD015122-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015122-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Systemic TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="bottom"> <p><b>Systemic TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> percutaneous nephrolithotomy <br/><b>Setting:</b> inpatient <br/><b>Intervention:</b> Systemic TXA <br/><b>Comparison:</b> No TXA (placebo or usual care) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interpretation</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with No TXA (placebo or usual care)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with Systemic TXA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Blood transfusion</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>1353<br/>(9 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b><br/>(0.27 to 0.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA probably reduces transfusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>61 fewer per 1000</b><br/>(81 fewer to 27 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce transfusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 fewer per 1000</b><br/>(42 fewer to 14 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Stone‐free rate</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>603<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.11</b><br/>(0.98 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may increase stone‐free rates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>620 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>68 more per 1000</b><br/>(12 fewer to 168 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may increase stone‐free rates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>83 more per 1000</b><br/>(15 fewer to 204 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Thromboembolic events</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>841<br/>(6 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RD0.00</b><br/>(‐0.01 to 0.01)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is probably no difference in how TXA effects thromboembolic events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to estimate</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>602<br/>(4 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 5.22</b><br/>(0.52 to 52.72) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may increase adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>98 more per 1000</b><br/>(11 fewer to 1,000 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Secondary interventions</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>319<br/>(2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b><br/>(0.84 to 1.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may have little to no effect on secondary interventions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42 more per 1000</b><br/>(44 fewer to 158 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Major surgical complications</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>733<br/>(5 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.36</b><br/>(0.21 to 0.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA probably reduces major surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>83 fewer per 1000</b><br/>(103 fewer to 49 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce major surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 fewer per 1000</b><br/>(32 fewer to 16 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor surgical complications</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>733<br/>(5 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.71</b><br/>(0.45 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce minor surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>396 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>115 fewer per 1000</b><br/>(218 fewer to 40 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Unplanned hospitalizations or readmissions</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>189<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Verylow</b><sup>a,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.55</b><br/>(0.45 to 5.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We are very uncertain how TXA effects unplanned hospitalizations or readmissions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 more per 1000</b><br/>(23 fewer to 180 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital length of stay</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 0.5 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1151<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean hospital length of stay was 4.72 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.52 days lower</b><br/>(0.93 lower to 0.11 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA may reduce hospital length of stay</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MCID:</b> minimally clinically important difference; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>RD:</b> risk difference; <b>TXA:</b> tranexamic acid </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rated down by one level (‐1) for risk of bias due to concerns over performance, detection and/or selective reporting bias. </p> <p><sup>b</sup>Based on pooled control event rate in the non‐TXA group. </p> <p><sup>c</sup>Rated down by one level (‐1) for imprecision due to wide confidence intervals consistent with both a decrease and no change. </p> <p><sup>d</sup>Based on large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>). </p> <p><sup>e</sup>Rated down by one level (‐1) for inconsistency due to clinically relevant inconsistency and high I‐square; we did not rate down further for imprecision. </p> <p><sup>f</sup>Risk difference was calculated for thromboembolic events as there were no thromboembolic events in intervention and/or control groups in 5 out of 6 studies. </p> <p><sup>g</sup>Rated down by one level (‐1) for imprecision due to wide confidence intervals consistent with both an increase and no change. </p> <p><sup>h</sup>Rated down by two levels (‐2) for imprecision due to wide confidence intervals consistent with an increase, no change or a decrease. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Systemic TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015122-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topical TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Percutaneous nephrolithotomy <br/><b>Setting:</b> Inpatients<br/><b>Intervention:</b> Topical TXA <br/><b>Comparison:</b> No TXA (placebo or usual care) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Interpretation</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with No TXA (placebo or usual care)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with Topical TXA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Blood transfusion</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.40</b><br/>(0.20 to 0.81) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA probably reduces blood transfusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 fewer per 1000</b><br/>(100 fewer to 24 fewer) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce blood transfusions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 fewer per 1000</b><br/>(46 fewer to 11 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Stone‐free rate</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b><br/>(0.99 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may improve stone‐free rates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>57 more per 1000</b><br/>(8 fewer to 139 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may improve stone‐free rates</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>757 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53 more per 1000</b><br/>(8 fewer to 129 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Thromboembolic events</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RD 0.00</b> (‐0.01 to 0.01)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is probably no difference in how TXA effects thromboembolic events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to estimate</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse event</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RD 0.00</b> (‐0.01 to 0.01)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There is probably no difference in how TXA effects adverse events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unable to estimate</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Secondary interventions</b> </p> <p>Follow‐up period: 90 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We found no evidence for the outcome of secondary interventions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Major surgical complications</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.69</b><br/>(0.45 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce major surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>210 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>65 fewer per 1000</b><br/>(116 fewer to 13 more) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce major surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 fewer per 1000</b><br/>(23 fewer to 2 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Minor surgical complications</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 5%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.73</b><br/>(0.59 to 0.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>TXA may reduce minor surgical complications</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>520 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>140 fewer per 1000</b><br/>(213 fewer to 47 fewer) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Unplanned hospitalizations or readmissions</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 2%</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>0<br/>(0 studies) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We found no evidence for the outcome of unplanned hospitalizations or readmissions</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital length of stay</b> </p> <p>Follow‐up period: 30 days</p> <p>Assumed MCID: absolute risk difference ≥ 0.5 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean hospital length of stay was 3.39 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.26 days lower</b><br/>(1.49 lower to 1.03 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA probably reduces hospital length of stay</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>MCID:</b> minimally clinically important difference; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>RD:</b> risk difference; <b>TXA:</b> tranexamic acid </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Rated down by one level (‐1) for to risk of bias due to concerns over performance, detection and/or selective reporting bias. </p> <p><sup>b</sup>Based on pooled control event rate in the non‐TXA group. </p> <p><sup>c</sup>Rated down by one level (‐1) for imprecision due to wide confidence intervals consistent with both a decrease and no change. </p> <p><sup>d</sup>Based on large international observational study (<a href="./references#CD015122-bbs2-0035" title="dela RosetteJ , AssimosD , DesaiM , GutierrezJ , LingemanJ , ScarpaR , et al, CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. Journal of Endourology2011;25(1):11-7. [PMID: 21247286]">de la Rosette 2011</a>). </p> <p><sup>e</sup>Rated down by one level (‐1) for imprecision due to wide confidence intervals consistent with both an increase and no change. </p> <p><sup>f</sup>Risk difference was calculated for thromboembolic events as there were no thromboembolic events in the intervention nor the control groups. </p> <p><sup>g</sup> Risk difference was calculated for adverse events as there were no adverse events in the intervention nor the control groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015122-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline Characteristics and Demographics of Included Studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study Name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Trial Period (year to year)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting/Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Description and Total # of Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Male:Female</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean Age</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean BMI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration of follow up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and Comparators <sup>a</sup> </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Bansal 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jan 2009 to June 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients with renal calculi planned to undergo PCNL</p> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>116:84</p> <p>Control</p> <p>109:91</p> <p>Overall</p> <p>225:175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>32.7</p> <p>Control:</p> <p>34.7</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>22.5</p> <p>Control:</p> <p>22.9</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>0.1% tranexamic acid solution (1000 mg in 1 L of normal saline)</p> <p>Control</p> <p>10 mL distilled water (placebo) in 1 L of normal saline</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Batagello 2021</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 May 2016 to 21 May 2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 years and older, with complex kidney stones (Guy’s stone score of 3 and 4)</p> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>32:61</p> <p>Control</p> <p>31:65</p> <p>Overall: 63:126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>44</p> <p>Control:</p> <p>45</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>26.4</p> <p>Control: 27.4</p> <p>Overall: Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1g of TXA in 250 mL saline (IV) over 15 mins</p> <p>Control:</p> <p>0.9% NaCl 250 mL (IV) over 15 minutes</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Iskakov 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jan 2013 to June 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Kazakhstan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 patients age 18 to 75 years</p> <p>with nephrolithiasis undergoing PCNL</p> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>35:47</p> <p>Control</p> <p>47:35</p> <p>Overall:</p> <p>82:82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>47.3</p> <p>Control:</p> <p>45.8</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>29.4</p> <p>Control:</p> <p>27.9</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>10 mL TXA to 200 mL saline solution (IV) immediately before surgery</p> <p>Control:</p> <p>No intervention</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Kumar 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jan 2011 to June 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 participants undergoing PCNL for renal stone disease</p> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>58:42</p> <p>Control:</p> <p>54:46</p> <p>Overall:</p> <p>112:88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA: 37.9</p> <p>Control: 39.9</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>68 patients with BMI &lt; 30; 32 patients with BMI &gt; 30</p> <p>Control:</p> <p>73 patients with BMI &lt; 30; 27 patients with BMI &gt; 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimum of 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 gm TXA IV followed by 3 500 mg oral dosages at 8 hr interval</p> <p>Control:</p> <p>Usual care</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Maghsoudi 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Not reported</p> <p>Control:</p> <p>Not reported</p> <p>Overall:</p> <p>185:87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>"Group 2" 44.2</p> <p>"Group 3" 45.5</p> <p>Control:</p> <p>48.7</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>"Group 2" ‐ 15mg/kg TXA injected anesthesia induction and after 12 hours three doses of 500 mg were injected every 8 hours. </p> <p>"Group 3" ‐</p> <p>10mg/kg TXA injected at anesthesia induction and after 12 hours three doses of 250 mg were injected every 8 hours </p> <p>Control:</p> <p>Usual care</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mohammadi 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Jan 2014 to Nov 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patients who underwent PCNL for staghorn calculi</p> <p>(Group 1 = stones &gt; 4mm;</p> <p>Group 2 = stones &lt; 4mm)</p> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1 </p> <p>TXA: 25:5</p> <p>Control: 21:9</p> <p>Group 2 </p> <p>TXA: 21:9</p> <p>Control: 24:6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1 </p> <p>TXA: 42.8</p> <p>Control: 43.6</p> <p>Group 2 </p> <p>TXA: 41.1</p> <p>Control: 41.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group 1 </p> <p>TXA: 25.7</p> <p>Control: 25.1</p> <p>Group 2 </p> <p>TXA: 23.70</p> <p>Control: 24.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1 g of TXA intravenously for 12 hours until discharge and then orally following discharge for 1 week </p> <p>Control:</p> <p>1 g of normal saline until discharge</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mohammadi Sichani 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sept 2016 to Nov 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 18 years of age, normal functioning contralateral kidney (Serum Cr of 1.5 mg/dL or less) </p> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>45:19</p> <p>Control:</p> <p>44:22</p> <p>Overall:</p> <p>89:41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>45.9</p> <p>Control:</p> <p>45.1</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>24.4</p> <p>Control:</p> <p>25.2</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1 g of TXA (IV) at start of procedure, then 1g q8 hrs for first 48 hrs (max.total dose of 6 g) </p> <p>Control:</p> <p>Saline solution</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mokhtari 2021</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013 to 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient</p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney or upper ureteral stone (&gt; 2 cm at pelvic/upper calices, &gt; 1.5 cm at lower calices), failed ESWL </p> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>28:26</p> <p>Control:</p> <p>30:24</p> <p>Overall:</p> <p>58:50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA: 39.5</p> <p>Control:</p> <p>42.4</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1 g TXA (IV) at start of procedure, 5 mg (PO) q8 hrs for 3 days</p> <p>Control: normal saline, then placebo capsules q8 hrs for 3 days</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rashid 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>March 2017 to Nov 2017</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Iraq</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults age &gt; 18 years with renal stones who failed shock wave lithotripsy</p> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control:</p> <p>17:8</p> <p>TXA:</p> <p>16:9</p> <p>Overall:</p> <p>33:17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control:</p> <p>48.9</p> <p>TXA:</p> <p>48.1</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control:</p> <p>26.7</p> <p>TXA:</p> <p>28.6</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>1 gm (10 cc) of the TXA 20 minute before surgery</p> <p>Control:</p> <p>10 cc of normal saline injection</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Siddiq 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oct 2015 to April 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inpatient setting</p> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aged 16–75 years of both genders, undergoing PCNL for renal stone size of more than 2 cm </p> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>72:48</p> <p>Control:</p> <p>82:38</p> <p>Overall:</p> <p>154:86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>41</p> <p>Control</p> <p>40</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>25.7</p> <p>Control</p> <p>26.2</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Injection 1 gram of TXA</p> <p>Control:</p> <p>Injection 1 gram of placebo</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>BMI:</b> body mass index; <b>IV:</b> invtravenous(ly); <b>PCNL:</b> percutaneous nephrolithotomy; <b>PO:</b> per oral; <b>TXA:</b> tranexamic acid </p> <p><sup>a</sup> Intervention and Comparators = route and dose of TXA vs placebo (or usual care, etc.) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline Characteristics and Demographics of Included Studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015122-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Clinical Characteristics of Included Studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study Name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean Stone Size</b> </p> <p><b>(mm)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Stone location</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Access Size <sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Access</b> </p> <p><b>Location <sup>b</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of access sites <sup>c</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Stone Surface area ± SD (cm<sup>2</sup>)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Bansal 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Staghorn 22</p> <p>Control:</p> <p>Staghorn 31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA</p> <p>2.79 (± 2.12)</p> <p>Control</p> <p>2.91 (± 2.05)</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Batagello 2021</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>46.8</p> <p>Control:</p> <p>49.3</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 24 Fr for control group</p> <p>and TXA group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Supra 24</p> <p>Infra 69</p> <p>Control:</p> <p>Supra 18</p> <p>Infra 78</p> <p>Overall:</p> <p>Supra 42</p> <p>Infra 147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 72</p> <p>Multiple 21</p> <p>Control:</p> <p>Single 67 Multiple 29</p> <p>Overall:</p> <p>Single 139</p> <p>Multiple 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Iskakov 2016</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Pelvis 21</p> <p>Lower calyx 6</p> <p>Pelvis+calyx 6</p> <p>Proximal ureter 4</p> <p>Upper calyx 2</p> <p>Middle calyx 0</p> <p>Staghorn 43</p> <p>Control:</p> <p>Pelvis 28</p> <p>Lower calyx 3</p> <p>Pelvis+calyx 4</p> <p>Proximal ureter 7</p> <p>Upper calyx 0</p> <p>Middle calyx 3</p> <p>Staghorn 37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 24 Fr for control group</p> <p>and TXA group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 82</p> <p>Multiple 0</p> <p>Control:</p> <p>Single 82</p> <p>Multiple 0</p> <p>Overall:</p> <p>Single 82</p> <p>Multiple 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>6.62 (± 0.67)</p> <p>Control:</p> <p>5.22 (± 0.46)</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Kumar 2013</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Staghorn 16</p> <p>Control:</p> <p>Staghorn 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 24 Fr for control group</p> <p>and TXA group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 80</p> <p>Mulitple 20</p> <p>Control:</p> <p>Single 76</p> <p>Multiple 24</p> <p>Overall:</p> <p>Single 156</p> <p>Multiple 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>3.79 (± 3.46)</p> <p>Control:</p> <p>3.73 (± 2.99)</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Maghsoudi 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>"Group 2" 5.89</p> <p>"Group 3" 5.92</p> <p>Control:</p> <p>5.95</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mohammadi 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 patients with stones &gt; 40 mm (Group 1)</p> <p>60 patients with stones &lt; 40 mm</p> <p>(Group 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mohammadi Sichani 2019</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 24 Fr for control group</p> <p>and TXA group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 37</p> <p>Multiple 27</p> <p>Control:</p> <p>Single 46</p> <p>Multiple 20</p> <p>Overall:</p> <p>Single 83</p> <p>Multiple 47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>3.45 (± 1.52)</p> <p>Control:</p> <p>3.93 (± 1.76)</p> <p>Overall:</p> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mokhtari 2021</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>36.2</p> <p>Control: 35.8</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Upper calyx 6</p> <p>Pelvis 0</p> <p>Lower calyx 37</p> <p>Control:</p> <p>Upper calyx 8</p> <p>Pelvis 0</p> <p>Lower calyx 30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rashid 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Single 21</p> <p>Multiple 4</p> <p>Control:</p> <p>Single 23</p> <p>Multiple 2</p> <p>Overall:</p> <p>Single 44</p> <p>Multiple 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Siddiq 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>21.5</p> <p>Control:</p> <p>31.8</p> <p>Overall:</p> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Upper Calyx 24</p> <p>Pelvis 30</p> <p>Lower Calyx 51</p> <p>Multiple Calyces 15</p> <p>Control:</p> <p>Upper Calyx 26</p> <p>Pelvis 31</p> <p>Lower Calyx 49</p> <p>Multiple Calyces 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>≥ 24 Fr 107</p> <p>&lt; 24 Fr 13</p> <p>Control:</p> <p>≥ 24 Fr</p> <p>109</p> <p>&lt; 24 Fr</p> <p>11</p> <p>Overall:</p> <p>≥ 24 Fr</p> <p>216</p> <p>&lt; 24 Fr</p> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TXA:</p> <p>Supra 54</p> <p>Infra 66</p> <p>Control:</p> <p>Supra 57</p> <p>Infra 63</p> <p>Overall:</p> <p>Supra 111</p> <p>Infra 129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>Fr:</b> French gauge; <b>SD:</b> standard deviation; <b>TXA:</b> tranexamic acid </p> <p><sup>a</sup> Access size = ≥ 24 Fr (#) vs &lt; 24 Fr (#) </p> <p><sup>b</sup> Access location = supracostal vs infracostal </p> <p><sup>c</sup> Number of access sites = single (#) / multiple (#) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Clinical Characteristics of Included Studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/full#CD015122-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015122-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic TXA vs No TXA (placebo or usual care)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.27, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Stone‐free rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.98, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.22 [0.52, 52.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Secondary interventions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.84, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Major Surgical complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.21, 0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Minor surgical complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.45, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Unplanned hospitalizations or readmissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.45, 5.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Hospital length of stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.93, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Blood transfusion (Sensitivity analysis &amp; Risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.05, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Stone‐free rate (Sensitivity analysis &amp; Risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.12, 3.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Thromboembolic events (Sensitivity analysis &amp; Risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Secondary interventions (Sensitivity analysis &amp; Risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.86, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Major surgical Complications (Sensitivity analysis &amp; Risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.13, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Minor Surgical complications (Sensitivity analysis &amp; Risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.37, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Unplanned hospitalizations or readmissions (Sensitivity analysis &amp; Risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.45, 5.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Hospital length ofsStay (days) (Sensitivity analysis &amp; Risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.97, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Blood transfusion (Sensitivity analysis &amp; definition of stone freedom) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.08, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Stone‐free rate (Sensitivity analysis &amp; definition of stone freedom) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.95, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Thromboembolic events (Sensitivity analysis &amp; definition of stone freedom) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Adverse Eeents (Sensitivity analysis &amp; definition of stone freedom) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [0.06, 85.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Secondary interventions (Sensitivity analysis &amp; definition of stone freedom) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.86, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Major surgical complications (Sensitivity analysis &amp; definition of stone freedom) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.19, 0.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Minor surgical complications (Sensitivity analysis &amp; definition of stone freedom) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.42, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Unplanned hospitalizations or readmissions (Sensitivity analysis &amp; definition of stone freedom) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.45, 5.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Hospital length of stay (days) (Sensitivity analysis &amp; definition of Stone freedom) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.07 [‐1.68, ‐0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Systemic TXA vs No TXA (placebo or usual care)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015122-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical TXA vs No TXA (placebo or usual care)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Blood transfusion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.20, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Stone‐free rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.99, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Thromboembolic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.01, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Major surgical complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.45, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Minor surgical complications <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.59, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Hospital length of stay (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.26 [‐1.49, ‐1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topical TXA vs No TXA (placebo or usual care)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015122.pub2/references#CD015122-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015122.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015122-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015122-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015122-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015122-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD015122-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD015122-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD015122-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD015122-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015122-note-0008">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015122-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015122\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015122\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015122\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015122\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015122\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=JmNqPX1V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015122.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015122.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015122.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015122.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015122.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716122389"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015122.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716122393"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015122.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d97cc69e0f409',t:'MTc0MDcxNjEyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 